symbol,publishedDate,title,image,site,text,url,title_compound,text_compound
VRTX,2020-12-28,The 3 Best Healthcare Stocks to Buy for 2021,https://cdn.snapi.dev/images/v1/n/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6056802f2021-on-tablet-next-to-stethoscope-and-pillsjpgw700opresize.jpg,The Motley Fool,All three could be huge winners in the new year -- and over the long run.,https://www.fool.com/investing/2020/12/27/the-3-best-healthcare-stocks-to-buy-for-2021/,0.6369,0.6597
VRTX,2020-12-28,3 Surefire Stocks to Buy With Your $600 Stimulus Check,https://cdn.snapi.dev/images/v1/1/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6061962fgovernment-stimulus-check-cash-money-us-treasury-covid-19-gettyjpgw700opresize.jpg,The Motley Fool,Making money is easy when you're invested in high-quality businesses with clear-cut competitive advantages.,https://www.fool.com/investing/2020/12/26/3-surefire-stocks-to-buy-with-600-stimulus-check/,0.25,0.7269
VRTX,2020-12-24,Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know,https://cdn.snapi.dev/images/v1/k/5/biotech33.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed at $234.46 in the latest trading session, marking a -0.59% move from the prior day.",https://www.zacks.com/stock/news/1207637/vertex-pharmaceuticals-vrtx-stock-sinks-as-market-gains-what-you-should-know,0.34,0.0
VRTX,2020-12-24,"Where to Invest $5,000 Right Now",https://cdn.snapi.dev/images/v1/r/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6058402fgettyimages-1212176842jpgw700opresize.jpg,The Motley Fool,"If you're worried another market crash is imminent, you'll want to scoop up these three stocks soon.",https://www.fool.com/investing/2020/12/24/where-to-invest-5000-right-now/,0.0,-0.4588
VRTX,2020-12-24,The 3 Best Stocks for 2021,https://cdn.snapi.dev/images/v1/i/h/stocks101-12.jpg,The Motley Fool,"A beaten-down biotech, a streaming star, and a coronavirus testing giant could be well-rounded additions to your portfolio.",https://www.fool.com/investing/2020/12/24/the-3-best-stocks-for-2021/,0.6369,0.0
VRTX,2020-12-23,Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases,https://cdn.snapi.dev/images/v1/j/e/biotech4.jpg,Zacks Investment Research,Vertex (VRTX) signs a licensing agreement with privately held company Skyhawk Therapeutics to discover novel small molecules that modulate RNA splicing for treating serious diseases.,https://www.zacks.com/stock/news/1200726/vertex-vrtx-inks-deal-with-skyhawk-for-serious-diseases,-0.0772,0.6369
VRTX,2020-12-23,3 Beaten-Down Growth Stocks That Can Soar in 2021,https://cdn.snapi.dev/images/v1/b/j/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6056472fbusinessman-holds-dollar-sign-grass-pot-investing-gettyjpgw700opresize.jpg,The Motley Fool,These high-growth companies are big-time bargains for opportunistic investors.,https://www.fool.com/investing/2020/12/23/3-beaten-down-growth-stocks-that-can-soar-in-2021/,0.3818,-0.0258
VRTX,2020-12-22,Vertex Pharmaceuticals Enters New Partnership With RNA Expert Skyhawk Therapeutics,https://cdn.snapi.dev/images/v1/5/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6059292fbuying-something-from-doctor-gettyjpgw700opresize.jpg,The Motley Fool,The large biotech firm is just the latest deep-pocketed player to ink a heavily backloaded deal with the RNA-splicing specialist.,https://www.fool.com/investing/2020/12/22/vertex-pharmaceuticals-enters-new-partnership-with/,0.0,0.0
VRTX,2020-12-21,"Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations",https://cdn.snapi.dev/images/v1/z/w/press4---qaw25fhcms.jpg,Business Wire,BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that are responsive to TRIKAFTA based on in vitro data. SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDEC,https://www.businesswire.com/news/home/20201221005675/en/Vertex-Announces-FDA-Approvals-of-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-SYMDEKO%C2%AE-tezacaftorivacaftor-and-ivacaftor-and-KALYDECO%C2%AE-ivacaftor-for-Use-in-People-With-CF-With-Certain-Rare-Mutations/,0.2732,0.5574
VRTX,2020-12-21,3 Biotech Stocks That Could Explode Higher in 2021,https://cdn.snapi.dev/images/v1/z/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6056182fhigh-tech-laboratory-gettyjpgw700opresize.jpg,The Motley Fool,Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.,https://www.fool.com/investing/2020/12/21/3-biotech-stocks-that-could-explode-higher-in-2021/,0.0,0.0
VRTX,2020-12-21,5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential,https://cdn.snapi.dev/images/v1/z/j/biotech5.jpg,24/7 Wall Street,"After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.",https://247wallst.com/healthcare-business/2020/12/21/5-top-biotech-stocks-to-buy-for-2021-with-massive-upside-potential/,0.2023,0.3182
VRTX,2020-12-21,3 Top Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/k/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5677182ffinancial-health-stethoscope-money-cash-hundred-bills-medical-healthcarejpgw700opresize.jpg,The Motley Fool,Each of them should enjoy strong sales growth in 2021 and beyond.,https://www.fool.com/investing/2020/12/19/3-top-biotech-stocks-to-buy-right-now/,0.2023,0.8442
VRTX,2020-12-18,Vertex Pharmaceuticals (VRTX) Stock Moves -0.08%: What You Should Know,https://cdn.snapi.dev/images/v1/a/a/biotech37.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed at $236.72 in the latest trading session, marking a -0.08% move from the prior day.",https://www.zacks.com/stock/news/1181887/vertex-pharmaceuticals-vrtx-stock-moves-008-what-you-should-know,0.0,0.0
VRTX,2020-12-17,One Of These Red Hot Growth Stocks Is A Very Strong Buy Right Now,https://cdn.snapi.dev/images/v1/e/f/data-internet17.jpg,Seeking Alpha,One Of These Red Hot Growth Stocks Is A Very Strong Buy Right Now,https://seekingalpha.com/article/4395112-one-of-red-hot-growth-stocks-is-strong-buy-right-now,0.7346,0.7346
VRTX,2020-12-14,3 Surefire Stocks to Buy When the Stock Market Inevitably Crashes,https://cdn.snapi.dev/images/v1/m/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6045722fstock-market-crash-calling-bottom-gettyjpgw700opresize.jpg,The Motley Fool,Opportunistic investors should pounce on these proven winners during the next big decline.,https://www.fool.com/investing/2020/12/14/surefire-stocks-buy-stock-market-inevitably-crashe/,0.25,0.4588
VRTX,2020-12-14,"If You Have $1,000 and 5 Years to Wait, Buy These 2 Stocks Now",https://cdn.snapi.dev/images/v1/c/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6043382fgettyimages-1170740969-1jpgw700opresize.jpg,The Motley Fool,These disruptive biotech stocks could prove to be great investments in the long run.,https://www.fool.com/investing/2020/12/13/if-you-have-1000-and-5-years-to-wait-buy-these-2-s/,0.0,0.4215
VRTX,2020-12-14,"Watch Out bluebird bio, CRISPR Is on Your Heels",https://cdn.snapi.dev/images/v1/p/o/podc14---bsu7ei4sde.jpg,The Motley Fool,The battle for beta thalassemia and sickle cell disease patients is heating up.,https://www.fool.com/investing/2020/12/12/watch-out-bluebird-bio-crispr-is-on-your-heels/,0.0,-0.3818
VRTX,2020-12-14,3 Stocks That Are Giving Their Investors Coal in Their Stockings,https://cdn.snapi.dev/images/v1/2/m/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6044512fgettyimages-200268734-001jpgw700opresize.jpg,The Motley Fool,"Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.",https://www.fool.com/investing/2020/12/12/3-stocks-that-are-giving-their-investors-coal-in-t/,0.34,0.6705
VRTX,2020-12-10,Which Big Biotechs Short Sellers Favor Now,https://cdn.snapi.dev/images/v1/l/9/biotech40.jpg,24/7 Wall Street,"The short interest data is out for November 30, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.",https://247wallst.com/healthcare-business/2020/12/10/which-big-biotechs-short-sellers-favor-now/,0.4019,-0.1027
VRTX,2020-12-09,The Best Biotech Stock on the Market Right Now,https://cdn.snapi.dev/images/v1/a/7/ver.jpg,The Motley Fool,This biotech has it all.,https://www.fool.com/investing/2020/12/09/the-best-biotech-stock-on-the-market-right-now/,0.6369,0.0
VRTX,2020-12-03,Is Vertex Pharmaceuticals Stock a Buy?,https://cdn.snapi.dev/images/v1/v/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6026192fgettyimages-909176662jpgw700opresize.jpg,The Motley Fool,This high-flying biotech is trading on the cheap.,https://www.fool.com/investing/2020/12/03/is-vertex-pharmaceuticals-stock-a-buy/,0.0,0.0
VRTX,2020-11-30,Vertex: The Cheapest And Highest Quality Monopoly In The Market,https://cdn.snapi.dev/images/v1/d/m/biotech2.jpg,Seeking Alpha,"Currently trading at 5-year historical PEG and PE NTM of 0.7x and 19.9x, respectively, VRTX's monopoly in cystic fibrosis is being grossly underappreciated by sell-side analysts. Long-term international expansion and pipeline opportunities represent a $4.8Bn and $9.5Bn TAM, respectively.",https://seekingalpha.com/article/4392032-vertex-cheapest-and-highest-quality-monopoly-in-market,0.0,0.6705
VRTX,2020-11-27,Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years,https://cdn.snapi.dev/images/v1/u/r/press3---rgeg9caxt5.jpg,Business Wire,"LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI® (tezacaftor/ivacaftor) with KALYDECO® (ivacaftor), to include the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or one copy of the F508del mutation and one copy of one of 14 mutations",https://www.businesswire.com/news/home/20201127005216/en/Vertex-Announces-European-Commission-Approval-for-SYMKEVI%C2%AE-tezacaftorivacaftor-With-KALYDECO%C2%AE-ivacaftor-for-Eligible-Children-With-Cystic-Fibrosis-Ages-6-11-Years/,0.4767,0.6249
VRTX,2020-11-25,Big Biotech Short Sellers Seek Cover,https://cdn.snapi.dev/images/v1/x/s/biotech34.jpg,24/7 Wall Street,"The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.",https://247wallst.com/healthcare-business/2020/11/25/big-biotech-short-sellers-seek-cover/,0.0,-0.1027
VRTX,2020-11-23,5 Growth Stocks to Buy for a Biden Bull Market,https://cdn.snapi.dev/images/v1/d/v/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6013472fstock-bull-market-sp-500-dow-jones-nasdaq-invest-growth-gettyjpgw700opresize.jpg,The Motley Fool,"The stock market could hit new highs under Biden, with these companies offering especially appetizing growth prospects.",https://www.fool.com/investing/2020/11/21/5-growth-stocks-to-buy-for-a-biden-bull-market/,0.3818,0.6533
VRTX,2020-11-20,"Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says",https://cdn.snapi.dev/images/v1/m/e/medicine-1309148-1920-282.jpg,Benzinga,"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares have come under selling pressure recently, given investor concern regarding diversity in the pipeline for this cystic fibrosis-focused biopharma. The Vertex Analyst: Bernstein analyst Analyst Vincent Chen initiated coverage of Vertex with an Outperform rating and $275 price target.",https://www.benzinga.com/analyst-ratings/analyst-color/20/11/18466234/odds-of-vertexs-pipeline-success-arent-dismal-as-some-fear-bernstein-says,0.5747,0.0
VRTX,2020-11-19,Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies London Healthcare Conference (Transcript),https://cdn.snapi.dev/images/v1/3/j/transcript8---banwqan5uh.jpg,Seeking Alpha,Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies London Healthcare Conference (Transcript),https://seekingalpha.com/article/4390312-vertex-pharmaceuticals-incorporated-vrtx-presents-jefferies-london-healthcare-conference,0.0,0.0
VRTX,2020-11-16,Here are the stocks seeing the most insider buying this week,https://cdn.snapi.dev/images/v1/m/q/here-are-the-stocks-seeing-the-most-insider-buying-this-week---igcwu1aaze.jpg,CNBC Television,"CNBC's Brian Sullivan highlights the stocks seeing the most insider buying this week, on Worldwide Exchange, including names like Hanes and Vertex Pharma.",https://www.youtube.com/watch?v=dL9aXDvgS7k,0.0,0.3612
VRTX,2020-11-16,2 Top Pharma Stocks to Watch in November,https://cdn.snapi.dev/images/v1/y/0/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5997662fgettyimages-1050311874jpgw700opresize.jpg,The Motley Fool,Here are two intriguing pharma stocks that may make investors rich this November.,https://www.fool.com/investing/2020/11/15/2-top-pharma-stocks-to-watch-in-november/,0.2023,0.5574
VRTX,2020-11-16,"Last Week's Notable Insider Buys: Kraft, IBM, Vertex And More",https://cdn.snapi.dev/images/v1/s/n/stoc92.jpg,Benzinga,"Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was both before and after the elections.",https://www.benzinga.com/news/20/11/18372524/last-weeks-notable-insider-buys-kraft-ibm-vertex-and-more,0.0,0.8768
VRTX,2020-11-13,Got $250? 3 High-Growth Stocks on Sale to Buy Now,https://cdn.snapi.dev/images/v1/8/x/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6002902fsale-sign-led-discount-stock-invest-retire-gettyjpgw700opresize.jpg,The Motley Fool,A handful of high-flying stocks are now on sale and begging to be bought.,https://www.fool.com/investing/2020/11/13/got-250-3-high-growth-stocks-on-sale-to-buy-now/,0.0,0.0
VRTX,2020-11-09,Here's Why Vertex Pharmaceuticals Fell 23.4% in October,https://cdn.snapi.dev/images/v1/7/j/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5997932fdoctor-patient-2jpgw700opresize.jpg,The Motley Fool,"The biotech stopped development of a midstage drug, but the company has a backup plan.",https://www.fool.com/investing/2020/11/08/heres-why-vertex-pharmaceuticals-fell-234-in-octob/,0.0,-0.1154
VRTX,2020-11-05,Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age,https://cdn.snapi.dev/images/v1/h/g/press9---lfglzwby6v.jpg,Business Wire,"LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for KALYDECO® (ivacaftor) granules to include the treatment of infants with cystic fibrosis (CF) ages 4 months and older and weighing at least 5 kg who have the R117H mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G55",https://www.businesswire.com/news/home/20201105005062/en/Vertex-Announces-European-Commission-Approval-for-KALYDECO%C2%AE-ivacaftor-as-First-and-Only-CFTR-Modulator-to-Treat-Eligible-Infants-With-Cystic-Fibrosis-as-Early-as-Four-Months-of-Age/,0.7003,0.6249
VRTX,2020-11-04,CRISPR and Vertex Release Additional Data for Blood Disease Treatment,https://cdn.snapi.dev/images/v1/q/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5987192fdoctor-child-patinetjpgw700opresize.jpg,The Motley Fool,CTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.,https://www.fool.com/investing/2020/11/04/crispr-and-vertex-release-additional-data-for-bloo/,0.0,0.4019
VRTX,2020-11-03,"Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?",https://cdn.snapi.dev/images/v1/7/2/vertex-neurocrine-are-these-out-of-favor-healthcare-stocks-a-buy-as-vaccine-nears.jpg,Forbes,"Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme includes healthcare and pharmaceutical companies that have shown robust historical revenue growth.",https://www.forbes.com/sites/greatspeculations/2020/11/03/vertex-neurocrine-are-these-out-of-favor-healthcare-stocks-a-buy-as-vaccine-nears/,0.4019,0.8779
VRTX,2020-10-30,"Why Vertex Hit a Home Run With Its Q3 Results, but Few Are Cheering",https://cdn.snapi.dev/images/v1/h/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5974802fmale-healthcare-provider-giving-a-high-five-to-a-pediatric-patient-sitting-in-his-mothers-lapjpgw700opresize.jpg,The Motley Fool,The big biotech's recent clinical setback appears to be overshadowing its sizzling growth.,https://www.fool.com/investing/2020/10/30/why-vertex-hit-a-home-run-with-its-q3-results-but/,0.6652,0.3818
VRTX,2020-10-29,"Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q3 2020 Results - Earnings Call Transcript",https://cdn.snapi.dev/images/v1/f/k/transcript27.jpg,Seeking Alpha,"Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q3 2020 Results - Earnings Call Transcript",https://seekingalpha.com/article/4382925-vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q3-2020-results-earnings-call,0.0,0.0
VRTX,2020-10-29,Recap: Vertex Pharmaceuticals Q3 Earnings,https://cdn.snapi.dev/images/v1/t/2/biotech20.jpg,Benzinga,"Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) decreased 1.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 114.63% over the past year to $2.64, which beat the estimate of $2.32.",https://www.benzinga.com/news/earnings/20/10/18131303/recap-vertex-pharmaceuticals-q3-earnings,0.0,0.6705
VRTX,2020-10-28,7 Cutting-Edge Biotech Stocks for Tomorrow ,https://cdn.snapi.dev/images/v1/e/4/drugs41.jpg,InvestorPlace,"Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.",https://investorplace.com/2020/10/7-cutting-edge-biotech-stocks-for-tomorrow/,0.0,0.0772
VRTX,2020-10-28,Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals,https://cdn.snapi.dev/images/v1/t/6/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5961592fgettyimages-1069333236jpgw700opresize.jpg,The Motley Fool,These two rare-disease drug developers are experts at penetrating their markets.,https://www.fool.com/investing/2020/10/28/better-buy-vertex-pharmaceuticals-vs-alexion-pharm/,0.4404,0.0
VRTX,2020-10-27,3 Biotech Stocks I'd Buy Right Now,https://cdn.snapi.dev/images/v1/g/u/biotech23.jpg,The Motley Fool,Marketed products -- and work in the pipeline -- should translate into future growth for these shares.,https://www.fool.com/investing/2020/10/27/3-biotech-stocks-id-buy-right-now/,0.0,0.5859
VRTX,2020-10-27,Major Biotechs Have Short Sellers Looking Both Ways,https://cdn.snapi.dev/images/v1/p/5/biotech35.jpg,24/7 Wall Street,"The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.",https://247wallst.com/healthcare-business/2020/10/27/major-biotechs-have-short-sellers-looking-both-ways/,0.0,-0.1027
VRTX,2020-10-26,Were These Hedge Funds Right About Selling Vertex Pharmaceuticals Incorporated (VRTX)?,https://cdn.snapi.dev/images/v1/0/6/biotech5.jpg,Insider Monkey,"Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) changed recently.",https://www.insidermonkey.com/blog/were-these-hedge-funds-right-about-selling-vertex-pharmaceuticals-incorporated-vrtx-887030/,0.0,0.9016
VRTX,2020-10-22,Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth,https://cdn.snapi.dev/images/v1/g/b/biotech9---3ac60heeb1.jpg,Zacks Investment Research,Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://www.zacks.com/stock/news/1081064/vertex-pharmaceuticals-vrtx-reports-next-week-wall-street-expects-earnings-growth,0.3818,0.2263
VRTX,2020-10-20,Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?,https://cdn.snapi.dev/images/v1/t/h/biotech3.jpg,Zacks Investment Research,Is (VRTX) Outperforming Other Medical Stocks This Year?,https://www.zacks.com/stock/news/1078909/is-vertex-pharmaceuticals-vrtx-outperforming-other-medical-stocks-this-year,0.0,0.0
VRTX,2020-10-20,Pick These 5 Stocks With Superb Interest Coverage Ratio,https://cdn.snapi.dev/images/v1/h/r/asset-management19-40.jpg,Zacks Investment Research,"A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS Health (CVS), Amedisys (AMED) and Insperity (NSP) are sound enough to meet financial obligations.",https://www.zacks.com/stock/news/1078824/pick-these-5-stocks-with-superb-interest-coverage-ratio,0.7964,0.6597
VRTX,2020-10-20,Bet on These 5 Top-Ranked Stocks With Strong Sales Growth,https://cdn.snapi.dev/images/v1/v/r/asset-management20.jpg,Zacks Investment Research,"Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J.",https://www.zacks.com/stock/news/1078787/bet-on-these-5-top-ranked-stocks-with-strong-sales-growth,0.7096,0.836
VRTX,2020-10-20,Vertex Pharmaceuticals (VRTX) Enters Oversold Territory,https://cdn.snapi.dev/images/v1/g/q/biotech35.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.",https://www.zacks.com/stock/news/1078698/vertex-pharmaceuticals-vrtx-enters-oversold-territory,0.0,-0.0484
VRTX,2020-10-19,Vertex to Announce Third-Quarter 2020 Financial Results on October 29,https://cdn.snapi.dev/images/v1/v/x/conf19.jpg,Business Wire,"BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October 29, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the ""Investors"" s",https://www.businesswire.com/news/home/20201019005702/en/Vertex-to-Announce-Third-Quarter-2020-Financial-Results-on-October-29/,0.0,0.3182
VRTX,2020-10-19,5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates,https://cdn.snapi.dev/images/v1/n/v/drugs2.jpg,Zacks Investment Research,Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.,https://www.zacks.com/stock/news/1078363/5-big-pharma-biotech-stocks-set-to-trump-q3-earnings-estimates,0.0,0.25
VRTX,2020-10-19,7 Large Biotechs Expected to Outperform This Earnings Season,https://cdn.snapi.dev/images/v1/0/0/biotech5.jpg,24/7 Wall Street,Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.,https://247wallst.com/healthcare-business/2020/10/17/7-large-biotechs-expected-to-outperform-this-earnings-season/,0.0,0.2732
VRTX,2020-10-16,Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20%,https://cdn.snapi.dev/images/v1/z/k/biotech36.jpg,Seeking Alpha,Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20%,https://seekingalpha.com/article/4379424-excellent-entry-point-for-vertex-pharmaceuticals-after-giving-awayminus-20,0.7269,0.7269
VRTX,2020-10-16,Vertex (VRTX) Drops 20% After Failed Drug Trial,https://cdn.snapi.dev/images/v1/f/i/stocks141-6.jpg,Investopedia,Vertex Pharmaceuticals (VRTX) sold off on heavy volume after discontinuing trials of a promising liver disease treatment.,https://www.investopedia.com/vertex-vrtx-drops-20-after-failed-drug-trial-5082627,-0.5106,0.4019
VRTX,2020-10-16,Forget Snowflake! 2 Hyper-Growth Stocks I'd Rather Buy,https://cdn.snapi.dev/images/v1/r/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5737452fgettyimages-1127069581jpgw700opresize.jpg,The Motley Fool,"These two healthcare giants have a habit of beating the market, and they aren't about to stop.",https://www.fool.com/investing/2020/10/16/forget-snowflake-2-hyper-growth-stocks-id-rather-b/,-0.2942,-0.276
VRTX,2020-10-15,"4 Top Stock Trades for Friday: ZM, DKNG, VRTX, GME",https://cdn.snapi.dev/images/v1/d/f/intro.jpg,InvestorPlace,"Zoom Video, DraftKings, Vertex Pharma and GameStop were our top stock trades from Thursday. Here's a look at the charts.",https://investorplace.com/2020/10/4-top-stock-trades-for-friday-zm-dkng-vrtx-gme/,0.2023,0.2023
VRTX,2020-10-15,"Vertex Pulls Nasdaq Down, but Wall Street Loves Zoom",https://cdn.snapi.dev/images/v1/u/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5308742fgettyimages-1003599708jpgw700opresize.jpg,The Motley Fool,The stock market continued to lose ground on Thursday afternoon.,https://www.fool.com/investing/2020/10/15/vertex-pulls-nasdaq-down-wall-street-loves-zoom/,0.7227,-0.4019
VRTX,2020-10-15,Vertex (VRTX) is an Incredible Growth Stock: 3 Reasons Why,https://cdn.snapi.dev/images/v1/e/r/biotech11.jpg,Zacks Investment Research,Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.,https://www.zacks.com/stock/news/1076793/vertex-vrtx-is-an-incredible-growth-stock-3-reasons-why,0.3818,0.4939
VRTX,2020-10-15,Vertex Pharmaceuticals News: Why VRTX Stock Is Getting Slammed 20% Today,https://cdn.snapi.dev/images/v1/g/1/biotech8.jpg,InvestorPlace,Vertex Pharmaceuticals (VRTX) news for Thursday concerning bad results from one of its clinical trials is sending VRTX stock down. The post Vertex Pharmaceuticals News: Why VRTX Stock Is Getting Slammed 20% Today appeared first on InvestorPlace.,https://investorplace.com/2020/10/vertex-pharmaceuticals-news-slamming-vrtx-stock/,0.0,-0.5423
VRTX,2020-10-15,Vertex to End Phase II Study on AAT Deficiency Candidate,https://cdn.snapi.dev/images/v1/a/j/biotech6---ttrwnmty64.jpg,Zacks Investment Research,Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.,https://www.zacks.com/stock/news/1076503/vertex-to-end-phase-ii-study-on-aat-deficiency-candidate,0.0,0.5267
VRTX,2020-10-15,Why Vertex Pharmaceuticals Stock Is Slumping Today,https://cdn.snapi.dev/images/v1/t/p/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5898462fgettyimages-1183908006jpgw700opresize.jpg,The Motley Fool,Investors are concerned about Vertex's pipeline after a rare miss in the clinic.,https://www.fool.com/investing/2020/10/15/why-vertex-pharmaceuticals-stock-is-slumping-today/,0.0,-0.1531
VRTX,2020-10-15,Analysts say Vertex's stock is under pressure after drug development failure,https://cdn.snapi.dev/images/v1/1/0/106298733-1576513139338gettyimages-880891422---fkgvojnfrz.jpeg,Market Watch,"Shares of Vertex Pharmaceuticals Inc. were down 9.8% in premarket trading on Thursday, the day after the drug maker said it had stopped development of an experimental therapy aimed at treating Alpha-1 antitrypsinase deficiency, which can cause lung and liver disease. Vertex cited the therapy's safety and pharmacokinetic profile of VX-814 as observed in a Phase 2 clinical trial.",https://www.marketwatch.com/story/analysts-say-vertexs-stock-is-under-pressure-after-drug-development-failure-2020-10-15,-0.6705,0.4767
VRTX,2020-10-14,Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment,https://cdn.snapi.dev/images/v1/v/e/vert2---wlkyzqam7o.jpg,Investors Business Daily,Shares of Vertex plunged after hours Wednesday after the company announced it planned to stop testing on a drug designed to treat protein deficiencies. VRTX stock fell by double digits.,https://www.investors.com/news/technology/vtx-stock-tumbles-stops-testing-protein-deficiency-treatment/,-0.1531,0.4019
VRTX,2020-10-14,Vertex stock falls after protein-deficiency drug development stopped,https://cdn.snapi.dev/images/v1/a/s/asde13.jpg,Market Watch,"Vertex Pharmaceuticals Inc. VRTX stock fell in the extended session Wednesday after the biotech company said it would stop developing a drug to treat an inherited protein deficiency that can cause lung and liver disease. Vertex shares fell 9% after hours, following a 1.7% decline to close the regular session at $271.46.",https://www.marketwatch.com/story/vertex-stock-falls-after-protein-deficiency-drug-development-stopped-11602709656,-0.2263,0.4019
VRTX,2020-10-14,Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?,https://cdn.snapi.dev/images/v1/e/z/biotech34.jpg,Zacks Investment Research,Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://www.zacks.com/stock/news/1075788/will-vertex-vrtx-beat-estimates-again-in-its-next-earnings-report,0.0,0.6597
VRTX,2020-10-14,4 Growth Stocks You Can Safely Hold Through 2030,https://cdn.snapi.dev/images/v1/7/5/esy27.jpg,The Motley Fool,These high-growth companies offer competitive advantages that'll favor buy-and-hold investors.,https://www.fool.com/investing/2020/10/14/4-growth-stocks-you-can-safely-hold-through-2030/,0.7003,0.7096
VRTX,2020-10-12,Vertex Looks To Target 10% Of Cystic Fibrosis Population Not Yet Achieved By Its Current CFTR Modulators,https://cdn.snapi.dev/images/v1/z/o/biotech18.jpg,Seeking Alpha,Vertex Pharmaceuticals strikes a deal with Moderna for a second time to develop a gene-edited therapy for cystic fibrosis; first partnership entails the use of mRNA and the second is LNP.,https://seekingalpha.com/article/4378618-vertex-looks-to-target-10-of-cystic-fibrosis-population-not-yet-achieved-current-cftr,0.0,-0.3612
VRTX,2020-10-12,Short Sellers Need to Find a Clue on Major Biotechs,https://cdn.snapi.dev/images/v1/1/u/biotech9.jpg,24/7 Wall Street,"The short interest data are out for September 30, the most recent settlement date.",https://247wallst.com/healthcare-business/2020/10/12/short-sellers-need-to-find-a-clue-on-major-biotechs/,0.0,0.4588
VRTX,2020-10-12,Booming Gene Editing Market to Pep Up These 5 Biotech Stocks,https://cdn.snapi.dev/images/v1/v/e/biotech12.jpg,Zacks Investment Research,"Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.",https://www.zacks.com/stock/news/1074350/booming-gene-editing-market-to-pep-up-these-5-biotech-stocks,0.0,0.3612
VRTX,2020-10-09,"Investing $1,000 in These 3 Stocks Would Be a Really Smart Move Right Now",https://cdn.snapi.dev/images/v1/0/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5939852fwoman-holding-book-with-light-bulb-and-moneyjpgw700opresize.jpg,The Motley Fool,These stocks are in great shape to deliver strong growth over the long run.,https://www.fool.com/investing/2020/10/09/investing-1000-in-these-3-stocks-would-be-a-really/,0.4576,0.875
VRTX,2020-10-07,"Got $1,000? 3 Stocks to Buy if the Market Crashes",https://cdn.snapi.dev/images/v1/z/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5939932fstock-market-crash-plunge-dollar-newspaper-invest-dow-sp-500-gettyjpgw700opresize.jpg,The Motley Fool,A plunging stock market would be the perfect opportunity to put your money to work in these great companies.,https://www.fool.com/investing/2020/10/07/got-1000-3-stocks-to-buy-if-the-market-crashes/,0.0,0.891
VRTX,2020-10-06,Add These 5 Stocks With Impressive Interest Coverage Ratio,https://cdn.snapi.dev/images/v1/u/k/fod922-1.jpg,Zacks Investment Research,Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.,https://www.zacks.com/stock/news/1071442/add-these-5-stocks-with-impressive-interest-coverage-ratio,0.743,0.5994
VRTX,2020-10-05,3 Top Stocks to Buy in October,https://cdn.snapi.dev/images/v1/k/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5631972fgettyimages-1132660268gogfbjpgw700opresize-2.jpg,The Motley Fool,Three very different stocks with at least one thing in common -- huge growth prospects.,https://www.fool.com/investing/2020/10/04/3-top-stocks-to-buy-in-october/,0.2023,0.7269
VRTX,2020-10-05,What You Need to Know About Orphan Drug Designations,https://cdn.snapi.dev/images/v1/u/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5932382fgettyimages-1242453956jpgw700opresize.jpg,The Motley Fool,"Their addressable markets may be small, but that doesn't mean developers will fail to profit from these boundary-breaking drugs.",https://www.fool.com/investing/2020/10/04/what-you-need-to-know-about-orphan-drug-designatio/,0.0,-0.2263
VRTX,2020-10-05,2 Top Biotech Stocks to Buy in October,https://cdn.snapi.dev/images/v1/t/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5938112fgettyimages-1087219198jpgw700opresize.jpg,The Motley Fool,These companies show that specialization can be an excellent competitive strategy.,https://www.fool.com/investing/2020/10/04/2-top-biotech-stocks-to-buy-in-october/,0.2023,0.6597
VRTX,2020-10-05,Where Will Vertex Pharmaceuticals Be in 5 Years?,https://cdn.snapi.dev/images/v1/f/d/biotech40.jpg,The Motley Fool,"The biotech company is up more than 23% in 2020, but where will it be in five years?",https://www.fool.com/investing/2020/10/03/where-will-vertex-pharmaceuticals-be-in-5-years/,0.0,0.0
VRTX,2020-09-28,Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants,https://cdn.snapi.dev/images/v1/2/s/biotech18.jpg,Zacks Investment Research,Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.,https://www.zacks.com/stock/news/1068151/vertexs-kalydeco-gets-fda-nod-for-cystic-fibrosis-in-infants,0.0,0.9001
VRTX,2020-09-28,5 Jefferies High-Conviction Health Care Stocks May Be Huge Q4 Winners,https://cdn.snapi.dev/images/v1/w/t/stocks8-71.jpg,24/7 Wall Street,"With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at what should be an improving 2021 economy as we emerge from the COVID-19 pandemic restrictions.",https://247wallst.com/healthcare-business/2020/09/28/5-jefferies-high-conviction-health-care-stocks-may-be-huge-q4-winners/,0.8225,0.7506
VRTX,2020-09-25,Biotech Short Sellers Hike Their Bets,https://cdn.snapi.dev/images/v1/j/e/biotech30.jpg,24/7 Wall Street,"The short interest data are out for September 15, the most recent settlement date.",https://247wallst.com/healthcare-business/2020/09/25/biotech-short-sellers-hike-their-bets/,0.0,0.4588
VRTX,2020-09-25,FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age,https://cdn.snapi.dev/images/v1/h/4/press6-4.jpg,Business Wire,BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to less than six months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data. KALYDECO is already approved in the U.S. and EU for the trea,https://www.businesswire.com/news/home/20200925005076/en/FDA-Approves-KALYDECO%C2%AE-ivacaftor-as-First-and-Only-CFTR-Modulator-to-Treat-Eligible-Infants-With-CF-as-Early-as-Four-Months-of-Age/,0.6597,0.7964
VRTX,2020-09-24,Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators,https://cdn.snapi.dev/images/v1/0/x/press16-2.jpg,Business Wire,"BOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA",https://www.businesswire.com/news/home/20200924005175/en/Vertex-to-Present-New-Data-at-European-and-North-American-Virtual-Cystic-Fibrosis-Conferences-Highlighting-Long-Term-Use-of-CFTR-Modulators/,0.0,0.34
VRTX,2020-09-23,"Stock Market Crash 2.0: Where to Invest $1,000",https://cdn.snapi.dev/images/v1/t/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5923232fgettyimages-864893078jpgw700opresize.jpg,The Motley Fool,Buying and holding these growth stocks would be the best way to endure the market mayhem.,https://www.fool.com/investing/2020/09/23/stock-market-crash-20-where-to-invest-1000/,-0.4019,0.7783
VRTX,2020-09-21,Vertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should Know,https://cdn.snapi.dev/images/v1/q/a/biotech30.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed at $264 in the latest trading session, marking a -0.52% move from the prior day.",https://www.zacks.com/stock/news/1061322/vertex-pharmaceuticals-vrtx-stock-moves-052-what-you-should-know,0.0,0.0
VRTX,2020-09-17,Beyond Coronavirus: Moderna Teams Up With Vertex on Cystic Fibrosis Therapy,https://cdn.snapi.dev/images/v1/f/n/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5921572fdoctor-patient-stethoscopejpgw700opresize.jpg,The Motley Fool,This is the companies' second project to tackle the lung disease.,https://www.fool.com/investing/2020/09/17/beyond-coronavirus-moderna-teams-up-with-vertex-on/,0.0,0.0
VRTX,2020-09-17,"Stock Market Crash 2.0: Here Are 3 Stocks You'll Absolutely, Positively Want to Buy",https://cdn.snapi.dev/images/v1/k/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5308742fgettyimages-1003599708jpgw700opresize.jpg,The Motley Fool,These stocks are great candidates to buy on the dip -- especially if that dip is a big one.,https://www.fool.com/investing/2020/09/17/stock-market-crash-20-here-are-3-stocks-youll-abso/,0.376,0.6249
VRTX,2020-09-16,3 Nasdaq Stocks to Buy Off Their Corrective Bottoms,https://cdn.snapi.dev/images/v1/0/v/ees23-9.jpg,InvestorPlace,"The best Nasdaq stocks to buy aren’t those with the biggest capitalization gains, but those whose shares have put in the work on the price chart.
The post 3 Nasdaq Stocks to Buy Off Their Corrective Bottoms appeared first on InvestorPlace.",https://investorplace.com/2020/09/3-nasdaq-stocks-to-buy-off-their-corrective-bottoms/,0.0,0.7269
VRTX,2020-09-16,Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing,https://cdn.snapi.dev/images/v1/t/y/press18-7.jpg,Business Wire,"CAMBRIDGE & BOSTON, Mass.--(BUSINESS WIRE)--Moderna and Vertex establish new collaboration to treat cystic fibrosis using gene editing.",https://www.businesswire.com/news/home/20200916005915/en/Moderna-and-Vertex-Establish-New-Collaboration-to-Treat-Cystic-Fibrosis-Using-Gene-Editing/,0.4019,0.4019
VRTX,2020-09-15,Vertex Eyes Label Expansion of Triple Combo CF Drug in Europe,https://cdn.snapi.dev/images/v1/x/p/biotech32.jpg,Zacks Investment Research,Vertex's (VRTX) label expansion application Kaftrio in combination with Kalydeco gets accepted for review by the European Medicines Agency.,https://www.zacks.com/stock/news/1058583/vertex-eyes-label-expansion-of-triple-combo-cf-drug-in-europe,0.0,0.2732
VRTX,2020-09-14, Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation,https://cdn.snapi.dev/images/v1/c/c/press1-2.jpg,Business Wire,"LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO®* (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, eligible",https://www.businesswire.com/news/home/20200914005342/en/%C2%A0Vertex-Announces-European-Medicines-Agency-Type-II-Variation-Marketing-Authorization-Application-Validation-for-KAFTRIO%C2%AE-ivacaftortezacaftorelexacaftor-in-Combination-with-ivacaftor-in-People-with-One-Copy-of-the-F508del-Mutation/,0.0,0.7506
VRTX,2020-09-14,"Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash",https://cdn.snapi.dev/images/v1/w/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5614122f3-test-tubesjpgw700opresize.jpg,The Motley Fool,The long-term picture is bright for these healthcare stocks thanks to stable product revenue.,https://www.fool.com/investing/2020/09/13/got-5000-3-surefire-stocks-to-buy-ahead-of-the-nex/,-0.1779,0.7906
VRTX,2020-09-11,Short Sellers Hike Their Bets in Major Biotechs,https://cdn.snapi.dev/images/v1/o/o/biotech22-3.jpg,24/7 Wall Street,"The short interest data are out for August 31, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.",https://247wallst.com/healthcare-business/2020/09/11/short-sellers-hike-their-bets-in-major-biotechs-3/,0.0,-0.1027
VRTX,2020-09-11,3 Incredibly Strong Stocks to Buy That Should Thrive Even If the Stock Market Crashes Again,https://cdn.snapi.dev/images/v1/x/c/etf35-33.jpg,The Motley Fool,These rock-solid businesses should be resilient no matter what happens with the stock market or the economy.,https://www.fool.com/investing/2020/09/11/3-incredibly-strong-stocks-to-buy-that-should-thri/,0.5563,-0.2732
VRTX,2020-09-10,Vertex Pharmaceuticals Reports Positive Phase 3 Results in Children for Blockbuster CF Drug,https://cdn.snapi.dev/images/v1/u/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5913132fgettyimages-1190193669jpgw700opresize.jpg,The Motley Fool,The cystic fibrosis treatment specialist says it will submit a supplemental New Drug Application for Trikafta this year.,https://www.fool.com/investing/2020/09/10/vertex-pharmaceuticals-reports-positive-phase-3-re/,0.8176,0.0
VRTX,2020-09-10,Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals,https://cdn.snapi.dev/images/v1/n/w/press8-2.jpg,Business Wire,"BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company has completed a global Phase 3 study of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children ages 6 through 11 years old with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation, and based on the results will submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Ad",https://www.businesswire.com/news/home/20200910005580/en/Vertex-Announces-Positive-Phase-3-Study-TRIKAFTA%C2%AE/,0.743,0.0
VRTX,2020-09-09,CRISPR Stocks: Buy or Trade?,https://cdn.snapi.dev/images/v1/r/z/etf14.jpg,Zacks Investment Research,"Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?",https://www.zacks.com/stock/news/1056009/crispr-stocks-buy-or-trade,0.0,0.0
VRTX,2020-09-09,Could Vertex Pharmaceuticals Be a Millionaire-Maker Stock?,https://cdn.snapi.dev/images/v1/g/o/5036jpgwidth460quality85autoformatfitmaxsf7c6b95f0aa1891b02665c830f2dc0d7-2.jpg,The Motley Fool,The pharma giant controls a massive addressable market and has proven its ability to increase drug sales.,https://www.fool.com/investing/2020/09/09/could-vertex-pharmaceuticals-be-a-millionaire-make/,0.0,0.5574
VRTX,2020-09-04,"Next Coronavirus Market Crash: Where to Invest $1,000",https://cdn.snapi.dev/images/v1/4/e/653.jpg,The Motley Fool,These three stocks are among the few winners to emerge from the coronavirus stock market.,https://www.fool.com/investing/2020/09/04/next-coronavirus-market-crash-where-to-invest-1000/,-0.4019,0.4767
VRTX,2020-09-04,"Got $3,000? Buying These 3 Stocks Could Make You Rich",https://cdn.snapi.dev/images/v1/m/o/gettyimages-1047349788-1jpgw588-5.jpg,The Motley Fool,All you have to do is buy -- and wait.,https://www.fool.com/investing/2020/09/04/got-3000-buying-these-3-stocks-could-make-you-rich/,0.5574,0.0
VRTX,2020-09-02,Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations,https://cdn.snapi.dev/images/v1/x/8/biotech1.jpg,Zacks Investment Research,"Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.",https://www.zacks.com/stock/news/1051795/vertex-seeks-nod-for-cystic-fibrosis-drugs-for-rare-mutations,0.0,0.4767
VRTX,2020-09-01,"FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations",https://cdn.snapi.dev/images/v1/k/q/press13-2.jpg,Business Wire,"BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental New Drug Applications (sNDAs) for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor).",https://www.businesswire.com/news/home/20200901005393/en/FDA-Accepts-Vertex%E2%80%99s-Supplemental-New-Drug-Applications/,0.3182,0.2732
VRTX,2020-08-31,Why Is Vertex (VRTX) Down 3.4% Since Last Earnings Report?,https://cdn.snapi.dev/images/v1/e/a/biotech40.jpg,Zacks Investment Research,Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?,https://www.zacks.com/stock/news/1049514/why-is-vertex-vrtx-down-34-since-last-earnings-report,0.0,0.0
VRTX,2020-08-28,Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?,https://cdn.snapi.dev/images/v1/9/u/biotech28.jpg,Zacks Investment Research,Is  (VRTX) Outperforming Other Medical Stocks This Year?,https://www.zacks.com/stock/news/1049108/is-vertex-pharmaceuticals-vrtx-stock-outpacing-its-medical-peers-this-year,0.0,0.0
VRTX,2020-08-28,Biotech Industry Near-Term Outlook Modest Amid Coronavirus,https://cdn.snapi.dev/images/v1/d/p/biotech31.jpg,Zacks Investment Research,Biotech Industry Near-Term Outlook Modest Amid Coronavirus,https://www.zacks.com/commentary/1048937/biotech-industry-near-term-outlook-modest-amid-coronavirus,0.0,0.0
VRTX,2020-08-27,These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020,https://cdn.snapi.dev/images/v1/h/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5889852fgettyimages-1141977907jpgw700opresize.jpg,The Motley Fool,Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.,https://www.fool.com/investing/2020/08/27/these-10-healthcare-stocks-are-the-biggest-sp-500/,0.4767,0.0
VRTX,2020-08-26,Major Biotechs Scare Off Short Sellers,https://cdn.snapi.dev/images/v1/d/n/dna-3656587-1920-1.jpg,24/7 Wall Street,"The short interest data are out for August 14, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.",https://247wallst.com/healthcare-business/2020/08/26/major-biotechs-scare-off-short-sellers-5/,-0.4939,-0.1027
VRTX,2020-08-24,Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod,https://cdn.snapi.dev/images/v1/v/e/vedswq.jpg,Zacks Investment Research,Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.,https://www.zacks.com/stock/news/1046536/vertexs-triple-combo-cystic-fibrosis-pill-kaftrio-gets-eu-nod,0.0,0.6124
VRTX,2020-08-21,European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older,https://cdn.snapi.dev/images/v1/q/6/press2-4.jpg,Business Wire,"LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission (EC) has granted marketing authorization for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor to treat people with cystic fibrosis (CF) ages 12 years and older with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. For the firs",https://www.businesswire.com/news/home/20200821005298/en/European-Commission-Approves-KAFTRIO%C2%AE-ivacaftortezacaftorelexacaftor-Combination-Ivacaftor/,0.6597,0.5719
VRTX,2020-08-20,3 Biotech Stocks You Can Buy and Hold for the Next Decade,https://cdn.snapi.dev/images/v1/g/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5882102f2020-with-ladder-to-2030jpgw700opresize.jpg,The Motley Fool,Their approved treatment lineups and pipeline candidates should make them all winners through 2030 at least.,https://www.fool.com/investing/2020/08/20/3-biotech-stocks-you-can-buy-and-hold-for-the-next/,0.0,0.7096
VRTX,2020-08-18,Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative Strength,https://cdn.snapi.dev/images/v1/s/h/biotech14.jpg,Investors Business Daily,"Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's Business Daily.",https://www.investors.com/news/technology/stock-upgrades-vertex-pharmaceuticals-shows-rising-relative-strength-3/,0.4939,0.8481
VRTX,2020-08-13,5 Disruptive Biotech Stocks to Buy for the Future That Is Here,https://cdn.snapi.dev/images/v1/a/a/biotech1600-768x432.jpg,InvestorPlace,"Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.",https://investorplace.com/2020/08/5-disruptive-biotech-stocks-to-buy-for-the-future-that-is-here/,-0.3182,0.0
VRTX,2020-08-13,2 Revolutionary Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/t/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5452622fgettyimages-1086688132jpgw700opresize.jpg,The Motley Fool,Each of these companies has the potential to generate life-changing returns.,https://www.fool.com/investing/2020/08/13/2-revolutionary-biotech-stocks-to-buy-right-now/,0.0,0.0
VRTX,2020-08-11,Top Growth Stocks For August,https://cdn.snapi.dev/images/v1/4/4/top-growth-stocks-for-august.jpg,Forbes,"The US-China tensions continue to keep markets at bay, but growth companies continue to be leaders for the market overall. Our deep learning algorithms using  AI technology have rated some of Top Growth Stocks below if you're looking to invest long-term on some future prospects.",https://www.forbes.com/sites/qai/2020/08/11/top-growth-stocks/,0.5267,0.8735
VRTX,2020-08-10,Biotech's Q2:  Lots Of Candidates That May Deliver Alpha,https://cdn.snapi.dev/images/v1/5/0/5036jpgwidth460quality85autoformatfitmaxsf7c6b95f0aa1891b02665c830f2dc0d7-2.jpg,Seeking Alpha,"The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.",https://seekingalpha.com/article/4366770-biotechs-q2-lots-of-candidates-may-deliver-alpha?utm_source=feed_articles_stock_ideas_quick_picks&utm_medium=referral,0.0,-0.7269
VRTX,2020-08-07,Why Vertex Pharmaceuticals Is the Best Biotech Stock to Buy in August,https://cdn.snapi.dev/images/v1/v/x/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5852362fgettyimages-845311230jpgw700opresize.jpg,The Motley Fool,The momentum is not over for this company or its blockbuster cystic fibrosis drug.,https://www.fool.com/investing/2020/08/07/why-vertex-pharmaceuticals-is-the-best-biotech-sto.aspx,0.6369,0.5994
VRTX,2020-08-06,3 Pharmaceutical Stocks That Can Make You Rich,https://cdn.snapi.dev/images/v1/a/b/drugs47.jpg,The Motley Fool,Some of the most promising stocks on the market right now are pharmaceuticals.,https://www.fool.com/investing/2020/08/06/3-pharmaceutical-stocks-that-can-make-you-rich.aspx,0.5574,0.4576
VRTX,2020-08-06,2 Rock-Solid Pharma Stocks That Won't Flinch if the Market Crashes,https://cdn.snapi.dev/images/v1/c/z/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5857052fgettyimages-1130771131jpgw700opresize.jpg,The Motley Fool,These two stocks weathered the March crash without incident.,https://www.fool.com/investing/2020/08/06/2-rock-solid-pharma-stocks-that-wont-flinch-if-the.aspx,0.0,-0.4019
VRTX,2020-07-31,"Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up",https://cdn.snapi.dev/images/v1/m/i/biotech32.jpg,Zacks Investment Research,"Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.",https://www.zacks.com/stock/news/1029106/vertex-vrtx-q2-earnings-sales-beat-revenue-guidance-up,0.0,0.6705
VRTX,2020-07-31,How Vertex Pharmaceuticals Wowed With Its Q2 Results,https://cdn.snapi.dev/images/v1/e/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5848732fpharmacists-filling-pillsjpgw700opresize.jpg,The Motley Fool,There's a one-word answer: Trikafta.,https://www.fool.com/investing/2020/07/31/how-vertex-pharmaceuticals-wowed-with-its-q2-resul.aspx,0.5574,0.0
VRTX,2020-07-30,"Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call Transcript",https://cdn.snapi.dev/images/v1/d/p/transcript45-2.jpg,Seeking Alpha,"Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call Transcript",https://seekingalpha.com/article/4362716-vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q2-2020-results-earnings-call,0.0,0.0
VRTX,2020-07-30,Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates,https://cdn.snapi.dev/images/v1/q/m/biotech38-8.jpg,Zacks Investment Research,"Vertex (VRTX) delivered earnings and revenue surprises of 22.54% and 8.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?",https://www.zacks.com/stock/news/1028205/vertex-pharmaceuticals-vrtx-tops-q2-earnings-and-revenue-estimates,0.5106,0.128
VRTX,2020-07-30,Vertex Stock Rises After Second-Quarter Earnings Beat Views,https://cdn.snapi.dev/images/v1/e/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5284572ffemale-scientist-with-pipette-in-labjpgw700opresize.jpg,Investors Business Daily,"Vertex Pharmaceuticals late Thursday reported adjusted earnings of $2.61 per share on $1.52 billion in sales for its second quarter, both numbers well above expectations, and shares rose .
The post Vertex Stock Rises After Second-Quarter Earnings Beat Views appeared first on Investor's Business Daily.",https://www.investors.com/news/technology/vertex-stock-rises-second-quarter-earnings-beat-views/,0.0,0.6705
VRTX,2020-07-30,Vertex Reports Second-Quarter 2020 Financial Results,https://cdn.snapi.dev/images/v1/1/x/press15.jpg,Business Wire,"BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues. ""This has been an exceptional first half for Vertex on all fronts and most importantly, in our efforts to bring our CF medicines to more people around the world.",https://www.businesswire.com/news/home/20200730005957/en/Vertex-Reports-Second-Quarter-2020-Financial-Results/,0.0,0.3804
VRTX,2020-07-28,Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players,https://cdn.snapi.dev/images/v1/c/3/biotech12.jpg,Seeking Alpha,Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players,https://seekingalpha.com/article/4361562-vertex-pharmaceuticals-67-yoy-returns-4-downside-risk-calling-all-medium-term-players,-0.4767,-0.4767
VRTX,2020-07-27,Vertex Pharmaceuticals For A Strong Portfolio,https://cdn.snapi.dev/images/v1/v/s/biotech3.jpg,Seeking Alpha,Vertex Pharmaceuticals For A Strong Portfolio,https://seekingalpha.com/article/4361041-vertex-pharmaceuticals-for-strong-portfolio,0.5106,0.5106
VRTX,2020-07-27,Why Vertex (VRTX) Could Beat Earnings Estimates Again,https://cdn.snapi.dev/images/v1/p/3/biotech4.jpg,Zacks Investment Research,Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://www.zacks.com/stock/news/1016711/why-vertex-vrtx-could-beat-earnings-estimates-again,0.0,0.6597
VRTX,2020-07-27,3 Unstoppable Stocks to Buy Before the Next Market Crash,https://cdn.snapi.dev/images/v1/c/r/biotech17.jpg,The Motley Fool,The healthcare industry is a good place to shop for stocks to keep your portfolio healthy during the next market crash.,https://www.fool.com/investing/2020/07/25/3-unstoppable-stocks-to-buy-next-market-crash.aspx,-0.5423,0.4404
VRTX,2020-07-24,Stocks To Watch With Next Quarterly Report On Tap: Vertex Pharmaceuticals,https://cdn.snapi.dev/images/v1/a/z/biotech22.jpg,Investors Business Daily,IBD 50 and Sector Leaders member Vertex Pharmaceuticals is expected to report earnings on Jul. 30. It's trading now trading 6% below the 295.65 buy point from a second-stage flat.,https://www.investors.com/news/technology/stocks-to-watch-with-next-quarterly-report-on-tap-vertex-pharmaceuticals/,0.0,0.0
VRTX,2020-07-24,Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?,https://cdn.snapi.dev/images/v1/3/o/biotech15.jpg,Zacks Investment Research,"On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.",https://www.zacks.com/stock/news/1015618/can-trikafta-drive-vertexs-vrtx-revenues-in-q2-earnings,0.0,0.0
VRTX,2020-07-24,Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks,https://cdn.snapi.dev/images/v1/s/c/106298733-1576513139338gettyimages-880891422.jpeg,24/7 Wall Street,"The health care sector has been a big winner in 2020, far outpacing the Dow Jones industrial average and S&P 500.",https://247wallst.com/healthcare-business/2020/07/24/goldman-sachs-sees-big-gains-from-7-biotech-pharma-conviction-buy-stocks/,0.34,0.7906
VRTX,2020-07-20,Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation,https://cdn.snapi.dev/images/v1/z/l/press20.jpg,Business Wire,BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) ages 12 years and older who have one copy of the F508del mutation and one gating mutation (F/G) or one copy of the F508del mutation and one residual function mutation (F/RF). The study met its primary endpoint of mean absolute within-group change in percent predicted forced,https://www.businesswire.com/news/home/20200720005395/en/Positive-Phase-3-Study-Results-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor/,0.5574,-0.4588
VRTX,2020-07-20,"Tax software company Vertex to offer 21.2 million shares in planned IPO, priced at $14 to $16 each",https://cdn.snapi.dev/images/v1/s/3/biotech22.jpg,Market Watch,"Vertex Inc. VERX, set terms for its initial public offering on Monday, with plans to offer 21.2 million shares priced at $14 to $16 each.",https://www.marketwatch.com/story/tax-software-company-vertex-to-offer-212-million-shares-in-planned-ipo-priced-at-14-to-16-each-2020-07-20,0.296,0.296
VRTX,2020-07-17,Better Buy: Vertex Pharmaceuticals vs. Regeneron,https://cdn.snapi.dev/images/v1/q/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5820592ffemale-scientist-holding-2-test-tubesjpgw700opresize.jpg,The Motley Fool,Which stock wins in a battle of two big biotechs?,https://www.fool.com/investing/2020/07/17/better-buy-vertex-pharmaceuticals-vs-regeneron.aspx,0.4404,0.2732
VRTX,2020-07-16,"Vertex Pharmaceuticals Selects TRIA to Design Laboratory and Office for New 268,000 SF VCGT Research Site",https://cdn.snapi.dev/images/v1/l/m/press13.jpg,PRNewsWire,"BOSTON, July 16, 2020 /PRNewswire/ -- TRIA, a principal-led architecture firm with a focus on designing unique workspaces for science, technology, and corporate clients, announced today that it is designing a new cell and genetic therapies research site in the Boston area for Vertex.",https://www.prnewswire.com/news-releases/vertex-pharmaceuticals-selects-tria-to-design-laboratory-and-office-for-new-268-000-sf-vcgt-research-site-301095035.html,0.0,0.0
VRTX,2020-07-16,Vertex to Announce Second-Quarter 2020 Financial Results on July 30,https://cdn.snapi.dev/images/v1/k/z/conf12-2.jpg,Business Wire,"BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m.",https://www.businesswire.com/news/home/20200716005153/en/Vertex-Announce-Second-Quarter-2020-Financial-Results-July/,0.0,0.0
VRTX,2020-07-15,Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know,https://cdn.snapi.dev/images/v1/j/q/biotech5-2.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed at $295.11 in the latest trading session, marking a +0.44% move from the prior day.",https://www.zacks.com/stock/news/1006001/vertex-pharmaceuticals-vrtx-gains-but-lags-market-what-you-should-know,-0.0258,0.0
VRTX,2020-07-13,3 Absolutely Rock-Solid Stocks to Buy Before the Market Crashes Again,https://cdn.snapi.dev/images/v1/x/s/etf44-7.jpg,The Motley Fool,Be prepared for the next market downturn with these great stocks.,https://www.fool.com/investing/2020/07/12/3-absolutely-rock-solid-stocks-to-buy-before-the-m.aspx,0.0,0.7184
VRTX,2020-07-10,Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks,https://cdn.snapi.dev/images/v1/s/o/biotech23.jpg,Investors Business Daily,The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.,https://www.investors.com/news/technology/health-care-stocks-buy-watch/,0.4939,0.9538
VRTX,2020-07-09,Vertex Pharmaceuticals (VRTX) Stock Moves -0.18%: What You Should Know,https://cdn.snapi.dev/images/v1/m/f/biotech14.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.40, moving -0.18% from the previous trading session.",https://www.zacks.com/stock/news/1001259/vertex-pharmaceuticals-vrtx-stock-moves-018-what-you-should-know,0.0,0.0
VRTX,2020-07-07,5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm,https://cdn.snapi.dev/images/v1/s/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5697512fgloved-hands-holding-2-test-tubesjpgw700opresize.jpg,GuruFocus,"In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital.",https://www.gurufocus.com/news/1180274/5-greenblatt-magic-formula-biotech-stocks-to-weather-the-summer-coronavirus-storm,0.0,0.7003
VRTX,2020-07-07,They Can’t Go Up Every Day; Stocks Fade After Strong Start,https://cdn.snapi.dev/images/v1/c/w/asset-management17-43.jpg,Investors Business Daily,"Though the general market indexes faded by the close, a few breakouts are still worth mentioning.",https://www.youtube.com/watch?v=katajhpklo8,0.5106,0.2263
VRTX,2020-07-07,These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why,https://cdn.snapi.dev/images/v1/w/g/754485-stockmarket-istock-111524.jpg,Investors Business Daily,"The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
The post These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why appeared first on Investor's Business Daily.",https://www.investors.com/news/technology/biotech-stocks-best-biotech-companies-to-invest-in/,0.0,0.8779
VRTX,2020-07-03,5 Booming Biotech Stocks to Buy,https://cdn.snapi.dev/images/v1/3/h/biotech-stocks-to-buy-0720.jpg,Kiplinger,"These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.",https://www.kiplinger.com/investing/stocks/601016/booming-biotech-stocks-to-buy,0.0,0.0
VRTX,2020-07-03,"Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones",https://cdn.snapi.dev/images/v1/x/m/medical7.jpg,Investors Business Daily,"Teladoc Health, Dexcom, Vertex Pharmaceuticals, Seattle Genetics and West Pharmaceutical Services are medical stocks in or near buy zones.
The post Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones appeared first on Investor's Business Daily.",https://www.investors.com/news/medical-stocks-teladoc-dexcom-vertex-seattle-genetics-near-buy-points/,0.0,0.0
VRTX,2020-07-02,Better Buy: Vertex Pharmaceuticals vs. Galapagos,https://cdn.snapi.dev/images/v1/9/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5779842fgettyimages-506712062jpgw700opresize.jpg,The Motley Fool,Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?,https://www.fool.com/investing/2020/07/02/better-buy-vertex-pharmaceuticals-vs-galapagos.aspx,0.4404,0.7717
VRTX,2020-06-30,Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor),https://cdn.snapi.dev/images/v1/c/k/press5.jpg,Business Wire,"LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicines to include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with KALYDECO® (ivacaftor) 150 mg, ahead of the medicine’s anticipated approval by the European Commission. The new expanded agreement includes reimbursed access to Vertex’s currently licensed medicines — KALYDECO® (ivaca",https://www.businesswire.com/news/home/20200630005573/en/Vertex-Announces-Expansion-Reimbursement-Agreement-NHS-England/,0.4939,0.8591
VRTX,2020-06-30,Can Vertex (VRTX) Stock Continue to Grow Earnings?,https://cdn.snapi.dev/images/v1/s/n/biotech5.jpg,Zacks Investment Research,"If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).",https://www.zacks.com/stock/news/995166/can-vertex-vrtx-stock-continue-to-grow-earnings,0.0,0.5994
VRTX,2020-06-30,3 Reasons Why Vertex Is a Great Stock to Buy and Hold for the Long Term,https://cdn.snapi.dev/images/v1/3/h/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5308612f18-08-21-candle-stick-chart-with-stock-quotes-in-the-background-gettyimages-842444522jpgw700opresize.jpg,The Motley Fool,"Elements from the past, present, and future are reasons to be optimistic about this biotech star.",https://www.fool.com/investing/2020/06/30/3-reasons-why-vertex-is-a-great-stock-to-buy-and-h.aspx,0.6249,0.3182
VRTX,2020-06-29,Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?,https://cdn.snapi.dev/images/v1/n/n/biotech7.jpg,Zacks Investment Research,Is  (VRTX) Outperforming Other Medical Stocks This Year?,https://www.zacks.com/stock/news/994554/has-vertex-pharmaceuticals-vrtx-outpaced-other-medical-stocks-this-year,0.0,0.0
VRTX,2020-06-29,Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing,https://cdn.snapi.dev/images/v1/f/d/biotech29.jpg,Zacks Investment Research,"Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.",https://www.zacks.com/stock/news/994325/vertexs-triple-combo-cystic-fibrosis-pill-gets-chmp-backing,0.0258,0.7003
VRTX,2020-06-29,Market to Stay Northbound Despite Volatility: 5 Growth Picks,https://cdn.snapi.dev/images/v1/f/l/software40.jpg,Zacks Investment Research,"The worst of the market is long over.  Although, short-term volatility will continue due to COVID-19, overall market movement will remain positively sloped.",https://www.zacks.com/stock/news/994328/market-to-stay-northbound-despite-volatility-5-growth-picks,-0.2924,-0.1779
VRTX,2020-06-26,CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes,https://cdn.snapi.dev/images/v1/z/d/press8-2.jpg,Business Wire,LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the  European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with KALYDECO® (ivacaftor) 150 mg to treat people with cystic fibrosis (CF) ages 12 and older with one F508del mutation and one minimal function mutation (F/MF) or two F508del mutations (F/F) in the cystic fib,https://www.businesswire.com/news/home/20200626005211/en/CHMP-Grants-Positive-Opinion-KAFTRIO%C2%AE-ivacaftortezacaftorelexacaftor-Combination/,0.6705,0.743
VRTX,2020-06-24,Vertex Pharmaceuticals (VRTX) Stock Moves -1.56%: What You Should Know,https://cdn.snapi.dev/images/v1/5/0/biotech28.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $291.18, moving -1.56% from the previous trading session.",https://www.zacks.com/stock/news/991951/vertex-pharmaceuticals-vrtx-stock-moves-156-what-you-should-know,0.0,0.0
VRTX,2020-06-24,Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?,https://cdn.snapi.dev/images/v1/d/e/biotech2-2.jpg,Zacks Investment Research,"Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",https://www.zacks.com/stock/news/991585/vertex-vrtx-hits-fresh-high-is-there-still-room-to-run,0.3182,0.8121
VRTX,2020-06-23,What Pandemic? These 5 Large Caps Are Up More Than 25% YTD,https://cdn.snapi.dev/images/v1/f/t/software50.jpg,Zacks Investment Research,Several large-caps have skyrocketed during the first half of 2020 while the broad market is yet to fully recover from the impacts of pandemic.,https://www.zacks.com/stock/news/990813/what-pandemic-these-5-large-caps-are-up-more-than-25-ytd,0.0,0.0
VRTX,2020-06-22,"Where to Invest $1,000 If You're Worried the Stock Market Might Crash Again",https://cdn.snapi.dev/images/v1/q/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5521902fgettyimages-1086296760jpgw700opresize.jpg,The Motley Fool,"Even if the market goes down, these investing options should go up.",https://www.fool.com/investing/2020/06/21/where-to-invest-1000-if-youre-worried-the-stock-ma.aspx,-0.5994,0.0
VRTX,2020-06-16,Here Are 4 Stocks With Remarkable Interest Coverage Ratio,https://cdn.snapi.dev/images/v1/y/o/stockstobuymsn-4.jpg,Zacks Investment Research,A company that is capable of generating earnings well above its interest expense can withstand financial hardships.,https://www.zacks.com/stock/news/986251/here-are-4-stocks-with-remarkable-interest-coverage-ratio,0.765,0.7717
VRTX,2020-06-16,3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic,https://cdn.snapi.dev/images/v1/c/q/biotech39.jpg,Zacks Investment Research,"We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.",https://www.zacks.com/stock/news/986198/3-big-biotechs-poised-for-growth-amid-coronavirus-pandemic,0.5574,0.6486
VRTX,2020-06-16,Fed's Bond-Buying Plan Eases Second-Wave Fears: 5 Picks,https://cdn.snapi.dev/images/v1/t/a/communication37.jpg,Zacks Investment Research,"With the Fed announcing that it will buy corporate bonds to help an economy battered by the coronavirus pandemic, the stock market has found a new lease of life.",https://www.zacks.com/stock/news/985781/feds-bond-buying-plan-eases-second-wave-fears-5-picks,-0.128,0.4019
VRTX,2020-06-12,CRISPR Therapeutics and Vertex Pharmaceuticals Deliever New CTX001 Data,https://cdn.snapi.dev/images/v1/2/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5785672fbiotech-microscope-gettyjpgw700opresize.jpg,The Motley Fool,The partners reported encouraging results from the first four patients treated with the CRISPR-based gene-editing therapy.,https://www.fool.com/investing/2020/06/12/crispr-therapeutics-vertex-new-ctx001-data.aspx,0.0,0.5267
VRTX,2020-06-12,6 Safe Stocks to Weather the Storm,https://cdn.snapi.dev/images/v1/y/w/etf26-46.jpg,Zacks Investment Research,These companies have strong balance sheets and are expected to grow over the next few years.,https://www.zacks.com/stock/news/980276/6-safe-stocks-to-weather-the-storm,0.4404,0.5106
VRTX,2020-06-12,CRISPR Rally: The First Gene-Editing Drug Continues To Show Promise,https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5156432fdna-double-helix-made-of-dollar-signs-2.jpg,Investors Business Daily,"Crispr Therapeutics and Vertex Pharmaceuticals stocks popped Friday after the biotech companies unveiled updated results for a gene-editing drug in blood-disease treatment.
The post CRISPR Rally: The First Gene-Editing Drug Continues To Show Promise appeared first on Investor's Business Daily.",https://www.investors.com/news/technology/blood-disease-treatment-news-prods-shares-biotech-companies/,0.3182,0.3182
VRTX,2020-06-11,7 Great Biotech Stocks to Buy and Hold Now,https://cdn.snapi.dev/images/v1/t/q/biotech1600b-768x432.jpg,InvestorPlace,"As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.",https://investorplace.com/2020/06/biotech-stocks-to-buy-for-long-term/,0.6249,0.8225
VRTX,2020-06-10,Vertex's Kalydeco Wins Approval in EU for CF in Children,https://cdn.snapi.dev/images/v1/o/o/biotech40.jpg,Zacks Investment Research,Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.,https://www.zacks.com/stock/news/976229/vertexs-kalydeco-wins-approval-in-eu-for-cf-in-children,0.7783,0.34
VRTX,2020-06-09,Top Biotech Stocks for Q3 2020,https://cdn.snapi.dev/images/v1/8/o/business-1730089-1920-1-12.jpg,Investopedia,"These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.",https://www.investopedia.com/investing/biotech-stocks/,0.2023,0.8481
VRTX,2020-06-08,Vertex CEO Provided Best Value for Investors,https://cdn.snapi.dev/images/v1/f/v/biotech27.jpg,GuruFocus,"Among the most highly-paid pharmaceutical CEOs in 2019, Vertex Pharmaceuticals Inc.",https://www.gurufocus.com/news/1157394/vertex-ceo-provided-best-value-for-investors-,0.765,0.0
VRTX,2020-06-08,3 Top Biotech Stocks to Buy in June,https://cdn.snapi.dev/images/v1/g/6/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5769312f3-test-tubesjpgw700opresize.jpg,The Motley Fool,They have one big thing in common: great growth prospects.,https://www.fool.com/investing/2020/06/06/3-top-biotech-stocks-to-buy-in-june.aspx,0.2023,0.836
VRTX,2020-06-08,2 Healthcare Stocks That Have a Killer Advantage,https://cdn.snapi.dev/images/v1/7/b/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5769872fgettyimages-1128789429jpgw700opresize.jpg,The Motley Fool,These two companies will keep competitors at bay for many years to come.,https://www.fool.com/investing/2020/06/06/2-healthcare-stocks-that-have-a-killer-advantage.aspx,-0.5106,0.0
VRTX,2020-06-05,Why Coronavirus Test Firms Are Among 4 Key Health Care Stocks,https://cdn.snapi.dev/images/v1/5/4/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5284572ffemale-scientist-with-pipette-in-labjpgw700opresize.jpg,Investors Business Daily,The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.,https://www.investors.com/news/technology/health-care-stocks-buy-watch/,0.4939,0.9538
VRTX,2020-06-04,Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know,https://cdn.snapi.dev/images/v1/i/n/biotech35.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $272.82, moving -1.51% from the previous trading session.",https://www.zacks.com/stock/news/964392/vertex-pharmaceuticals-vrtx-dips-more-than-broader-markets-what-you-should-know,0.0,0.0
VRTX,2020-06-03,5 Strong Buy Growth Stocks for this Secular Bull Rally,https://cdn.snapi.dev/images/v1/4/2/754485-stockmarket-istock-111524.jpg,Zacks Investment Research,How can the stock market be near another all-time high with a pandemic and 40 million unemployed? Secular bull markets don't care about headlines.,https://www.zacks.com/stock/news/961336/5-strong-buy-growth-stocks-for-this-secular-bull-rally,0.7096,-0.3875
VRTX,2020-06-02,Vertex Pharmaceuticals Is a Biotech Play With No Coronavirus Exposure,https://cdn.snapi.dev/images/v1/y/k/biotech28.jpg,InvestorPlace,"VRTX stock is a biopharmaceutical with an A-Rating that has no stake in the risky race for a coronavirus treatment.
The post Vertex Pharmaceuticals Is a Biotech Play With No Coronavirus Exposure appeared first on InvestorPlace.",https://investorplace.com/2020/06/vrtx-stock-is-a-biotech-play-with-no-coronavirus-exposure/,0.0516,-0.4215
VRTX,2020-06-01,3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity,https://cdn.snapi.dev/images/v1/c/l/drugs27.jpg,Zacks Investment Research,Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery.,https://www.zacks.com/stock/news/957567/3-strong-pharmaceutical-and-biotech-stocks-to-buy-for-coronavirus-immunity,0.5106,0.0
VRTX,2020-06-01,2 Best Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/6/z/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5758552fgettyimages-495358386jpgw700opresize.jpg,The Motley Fool,Revenue is climbing at these biotech companies. And one of them is waiting for what could be an historic product approval.,https://www.fool.com/investing/2020/06/01/2-best-biotech-stocks-to-buy-right-now.aspx,0.6369,0.4767
VRTX,2020-05-29,Why Is Vertex (VRTX) Up 10.4% Since Last Earnings Report?,https://cdn.snapi.dev/images/v1/t/s/biotech12-2.jpg,Zacks Investment Research,Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?,https://www.zacks.com/stock/news/952143/why-is-vertex-vrtx-up-104-since-last-earnings-report,0.0,0.0
VRTX,2020-05-29,"Got $3,000? Here Are 3 Great Biotech Stocks to Buy Right Now",https://cdn.snapi.dev/images/v1/9/j/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5757612ftest-tubes-with-green-arrow-pointing-upjpgw700opresize.jpg,The Motley Fool,One big biotech and two small biotechs especially stand out as attractive picks.,https://www.fool.com/investing/2020/05/29/got-3000-here-are-3-great-biotech-stocks-to-buy-ri.aspx,0.6249,0.4404
VRTX,2020-05-27,VRTX vs. ILMN: Which Stock Should Value Investors Buy Now?,https://cdn.snapi.dev/images/v1/n/2/medical27.jpg,Zacks Investment Research,VRTX vs. ILMN: Which Stock Is the Better Value Option?,https://www.zacks.com/stock/news/947189/vrtx-vs-ilmn-which-stock-should-value-investors-buy-now,0.34,0.6486
VRTX,2020-05-27,Profit From 5 Stocks Likely to Beat on Earnings,https://cdn.snapi.dev/images/v1/8/7/specialty18.jpg,Zacks Investment Research,Bet on five stocks that are likely to outdo earnings estimates.,https://www.zacks.com/stock/news/946914/profit-from-5-stocks-likely-to-beat-on-earnings,0.4404,0.0
VRTX,2020-05-27,"S&P Reclaims 3,000: Buy 6 Stocks With More Than 25% Growth",https://cdn.snapi.dev/images/v1/a/z/semi29.jpg,Zacks Investment Research,"In the latest market rally driven by hopes surrounding potential coronavirus vaccines and reopening of the economy, the S&P 500 reclaimed its 3,000 level and is poised to rise further.",https://www.zacks.com/stock/news/946645/sp-reclaims-3000-buy-6-stocks-with-more-than-25-growth,0.4336,0.5859
VRTX,2020-05-26,Vertex Energy's Transformation Continues,https://cdn.snapi.dev/images/v1/e/s/biotech6.jpg,Seeking Alpha,Vertex Energy's Transformation Continues,https://seekingalpha.com/article/4350175-vertex-energys-transformation-continues,0.0,0.0
VRTX,2020-05-26,2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks,https://cdn.snapi.dev/images/v1/g/g/etf4.jpg,Zacks Investment Research,"As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.",https://www.zacks.com/stock/news/944732/2-top-factors-buoy-wall-street-since-memorial-day-5-picks,0.2023,0.5423
VRTX,2020-05-20,2 Top Biotech Picks for May,https://cdn.snapi.dev/images/v1/t/b/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5741692fgettyimages-1172482193jpgw700opresize.jpg,The Motley Fool,Here are the hottest companies coming up in the biotech sector next month.,https://www.fool.com/investing/2020/05/20/2-top-biotech-picks-for-may.aspx,0.2023,0.0
VRTX,2020-05-19,3 Great Stocks to Buy If You Get a Second Stimulus Check,https://cdn.snapi.dev/images/v1/m/w/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5748042fcovid-19-stimulus-checkjpgw700opresize.jpg,The Motley Fool,Uncle Sam could be sending more money your way in the not-too-distant future. Buying these stocks will put the extra cash to good use.,https://www.fool.com/investing/2020/05/19/3-great-stocks-to-buy-if-you-get-a-second-stimulus.aspx,0.6249,0.4404
VRTX,2020-05-19,5 Reasons Why Growth Stocks Will Soar Further,https://cdn.snapi.dev/images/v1/y/w/3okjn333-4.jpg,Zacks Investment Research,"A few positive developments on the vaccine front, unprecedented economic help, reopening of economies and some bullish economic datapoints should facilitate growth stocks ahead.",https://www.zacks.com/stock/news/932697/5-reasons-why-growth-stocks-will-soar-further,0.3818,0.836
VRTX,2020-05-19,"Major Indexes Defying ""Sell in May"" Adage: 5 Growth Picks",https://cdn.snapi.dev/images/v1/a/x/education2.jpg,Zacks Investment Research,"Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage ""Sell in May and go away.""",https://www.zacks.com/stock/news/932684/major-indexes-defying-sell-in-may-adage-5-growth-picks,0.3818,0.0
VRTX,2020-05-19,Bull of the Day: Vertex Pharma (VRTX),https://cdn.snapi.dev/images/v1/w/c/biotech15.jpg,Zacks Investment Research,Bull of the Day: Vertex Pharma (VRTX),https://www.zacks.com/commentary/931884/bull-of-the-day-vertex-pharma-vrtx,0.0,0.0
VRTX,2020-05-18,Surging Earnings Estimates Signal Good News for Vertex Pharmaceuticals (VRTX),https://cdn.snapi.dev/images/v1/7/m/biotech40.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.",https://www.zacks.com/stock/news/931503/surging-earnings-estimates-signal-good-news-for-vertex-pharmaceuticals-vrtx,0.4404,0.6369
VRTX,2020-05-18,Wall Street to Rally as Powell Talks Recovery: 5 Big Winners,https://cdn.snapi.dev/images/v1/f/4/semi1.jpg,Zacks Investment Research,Wall Street poised to gain after Powell expressed confidence that the U.S. economy will recover beginning summer.,https://www.zacks.com/stock/news/930968/wall-street-to-rally-as-powell-talks-recovery-5-big-winners,0.4767,0.8271
VRTX,2020-05-18,Buy These 4 Stocks With Attractive Interest Coverage Ratio,https://cdn.snapi.dev/images/v1/s/e/specialty8.jpg,Zacks Investment Research,Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.,https://www.zacks.com/stock/news/930916/buy-these-4-stocks-with-attractive-interest-coverage-ratio,0.7096,0.5994
VRTX,2020-05-15,Why Vertex's Stock Is Trading Higher Today,https://cdn.snapi.dev/images/v1/a/v/vert2.jpg,Benzinga,Vertex Pharmaceuticals (NASDAQ: VRTX) shares are trading higher after Argus Research maintained a Buy rating on the stock and raised its price target from $270 to $320.,https://www.benzinga.com/analyst-ratings/price-target/20/05/16047377/why-vertexs-stock-is-trading-higher-today,0.0,0.296
VRTX,2020-05-15,"Vertex Energy, Inc. (VTNR) CEO Ben Cowart on Q1 2020 Results - Earnings Call Transcript",https://cdn.snapi.dev/images/v1/l/d/transcript21.jpg,Seeking Alpha,"Vertex Energy, Inc. (VTNR) CEO Ben Cowart on Q1 2020 Results - Earnings Call Transcript",https://seekingalpha.com/article/4348003-vertex-energy-inc-vtnr-ceo-ben-cowart-on-q1-2020-results-earnings-call-transcript,0.2732,0.2732
VRTX,2020-05-14,3 Reasons Growth Investors Will Love Vertex (VRTX),https://cdn.snapi.dev/images/v1/a/u/biotech1.jpg,Zacks Investment Research,"Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.",https://www.zacks.com/stock/news/925395/3-reasons-growth-investors-will-love-vertex-vrtx,0.7783,0.5719
VRTX,2020-05-13,Taiwan-based live streaming company M17 raises $26.5 million Series D led by Vertex Growth,https://cdn.snapi.dev/images/v1/v/w/gettyimages-977559874jpgw600.jpg,TechCrunch,"M17, the Taiwan-based live streaming entertainment startup, announced that it has raised a $26.5 million Series D. The round was led by Vertex Growth Fund, with participation from Stonebridge Korea Unicorn Venture Fund, Innoven Capital Singapore, Kaga Electronics and ASE Global Group.",https://techcrunch.com/2020/05/13/taiwan-based-live-streaming-company-m17-raises-26-5-million-series-d-led-by-vertex-growth/,0.3818,0.6597
VRTX,2020-05-11,"Stocks Close Strong; Vertex, Ping Identity, Resmed Clear Buy Points",https://cdn.snapi.dev/images/v1/s/t/stocks151-70.jpg,Investors Business Daily,"Stocks close strong, led by growth; Vertex, Ping Identity, Resmed clear buy points.",https://www.youtube.com/watch?v=nwoChAQiE8M,0.7096,0.8176
VRTX,2020-05-11,5 Top Health Care Stocks to Buy Now on the Goldman Sachs Conviction List,https://cdn.snapi.dev/images/v1/r/o/biotech31-2.jpg,24/7 Wall Street,"We are only in May, but 2020 is already one of the most incredible years in stock market history.",https://247wallst.com/healthcare-business/2020/05/11/5-top-health-care-stocks-to-buy-now-on-the-goldman-sachs-conviction-list/,0.6124,0.0
VRTX,2020-05-11,Wall Street Resilient to Crisis-Era Jobless Rate: 5 Picks,https://cdn.snapi.dev/images/v1/f/2/semi2.jpg,Zacks Investment Research,Stocks finished last week in the green despite massive job losses as the market expects a sharp but short recession.,https://www.zacks.com/stock/news/918822/wall-street-resilient-to-crisis-era-jobless-rate-5-picks,0.0,-0.4715
VRTX,2020-05-11,3 Top Biotech Stocks to Buy in May,https://cdn.snapi.dev/images/v1/d/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5582712fcell-culturejpgw700opresize.jpg,The Motley Fool,These hot biotech stocks should be near the top of your list.,https://www.fool.com/investing/2020/05/10/3-top-biotech-stocks-to-buy-in-may.aspx,0.2023,0.2023
VRTX,2020-05-08,5 Biopharmas Where BofA Would Put Its Money To Work,https://cdn.snapi.dev/images/v1/m/i/microbiology-163521-1280-6.jpg,Benzinga,"Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing.",https://www.benzinga.com/analyst-ratings/analyst-color/20/05/15989612/5-biopharmas-where-bofa-would-put-its-money-to-work,0.0,0.128
VRTX,2020-05-08,4 Best Stocks to Buy for Stellar Earnings Growth,https://cdn.snapi.dev/images/v1/o/c/software16.jpg,Zacks Investment Research,We have selected four solid stocks that have striking earnings growth and positive estimate revisions.,https://www.zacks.com/stock/news/917781/4-best-stocks-to-buy-for-stellar-earnings-growth,0.7783,0.7783
VRTX,2020-05-08,3 Reasons to Buy Vertex Pharmaceuticals Stock Right Now,https://cdn.snapi.dev/images/v1/3/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5715502fgettyimages-1089374276jpgw700opresize.jpg,The Motley Fool,Vertex Pharmaceuticals’ stock has been providing market-beating returns of late. Here’s why it can continue outperforming.,https://www.fool.com/investing/2020/05/08/3-reasons-to-buy-vertex-pharmaceuticals-stock-righ.aspx,0.0,0.0
VRTX,2020-05-07,3 Market-Beating Growth Stocks,https://cdn.snapi.dev/images/v1/s/t/stocks7-58.jpg,Zacks Investment Research,3 Market-Beating Growth Stocks,https://www.zacks.com/commentary/917499/3-market-beating-growth-stocks,0.3818,0.3818
VRTX,2020-05-07,5 Stocks That Look Appealing on Relative Price Strength,https://cdn.snapi.dev/images/v1/q/k/gettyimages-1047349788-1jpgw588-2.jpg,Zacks Investment Research,Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.,https://www.zacks.com/stock/news/916517/5-stocks-that-look-appealing-on-relative-price-strength,0.4939,0.7717
VRTX,2020-05-06,Can Vertex (VRTX) Run Higher on Rising Earnings Estimates?,https://cdn.snapi.dev/images/v1/d/u/biotech11.jpg,Zacks Investment Research,"Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.",https://www.zacks.com/stock/news/915570/can-vertex-vrtx-run-higher-on-rising-earnings-estimates,0.0,0.6808
VRTX,2020-05-06,5 Top-Ranked Stocks to Tap Earnings Beat Potential,https://cdn.snapi.dev/images/v1/z/r/dowjones1600-768x432.jpg,Zacks Investment Research,"Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.",https://www.zacks.com/stock/news/915145/5-top-ranked-stocks-to-tap-earnings-beat-potential,0.0,0.1779
VRTX,2020-05-05,Deep Dive: These 10 S&P 500 companies increased sales faster than Amazon in a coronavirus-tainted quarter,https://cdn.snapi.dev/images/v1/e/d/edcew3r333.jpg,Market Watch,"We’re right in the thick of first-quarter earnings season, and while it is looking bad as consumers and companies suffer from the coronavirus shutdown, there are still companies that are growing rapidly.",https://www.marketwatch.com/story/these-10-sp-500-companies-increased-sales-faster-than-amazon-in-a-coronavirus-tainted-quarter-2020-05-05,0.4215,-0.743
VRTX,2020-05-05,Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio,https://cdn.snapi.dev/images/v1/g/r/gre45666-6.jpg,Zacks Investment Research,Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.,https://www.zacks.com/stock/news/913917/scoop-up-these-4-stocks-with-amazing-interest-coverage-ratio,0.8126,0.8957
VRTX,2020-05-05,4 Momentum Picks Screened - on Driehaus Strategy,https://cdn.snapi.dev/images/v1/s/t/stock-charts-11.jpg,Zacks Investment Research,Driehaus strategy is perfect for investors who have the propensity to take high levels of risk.,https://www.zacks.com/stock/news/913834/4-momentum-picks-screened-on-driehaus-strategy,0.0,0.3818
VRTX,2020-05-04,Here's My  Top Stock to Buy in May,https://cdn.snapi.dev/images/v1/z/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5709912fmay-with-1-on-notejpgw700opresize.jpg,The Motley Fool,There are three great reasons to buy this stock sooner rather than later.,https://www.fool.com/investing/2020/05/03/heres-my-top-stock-to-buy-in-may.aspx,0.2023,0.6249
VRTX,2020-05-01,Stocks End Week On A Downer,https://cdn.snapi.dev/images/v1/i/o/gettyimages-1047349788-1jpgw588.jpg,Investors Business Daily,Chip stocks sold again after President Trump threatened China with more tariffs.,https://www.youtube.com/watch?v=EvQRjo0K0No,0.0,-0.4588
VRTX,2020-04-30,"Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues",https://cdn.snapi.dev/images/v1/t/k/biotech15.jpg,Zacks Investment Research,"Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.",https://www.zacks.com/stock/news/909569/vertex-vrtx-q1-earnings-beat-trikafta-drives-cf-revenues,0.0,0.6705
VRTX,2020-04-29,Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q1 2020 Results - Earnings Call Transcript,https://cdn.snapi.dev/images/v1/5/w/transcript27.jpg,Seeking Alpha,Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q1 2020 Results - Earnings Call Transcript,https://seekingalpha.com/article/4341304-vertex-pharmaceuticals-incorporated-vrtx-ceo-reshma-kewalramani-on-q1-2020-results-earnings,0.0,0.0
VRTX,2020-04-29,Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates,https://cdn.snapi.dev/images/v1/o/f/biotech20.jpg,Zacks Investment Research,"Vertex (VRTX) delivered earnings and revenue surprises of 39.89% and 19.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?",https://www.zacks.com/stock/news/899500/vertex-pharmaceuticals-vrtx-q1-earnings-and-revenues-beat-estimates,0.0,0.128
VRTX,2020-04-29,Biotech Surges On Unexpected Guidance Boost For 2020 Amid Pandemic,https://cdn.snapi.dev/images/v1/9/7/973-2.jpg,Investors Business Daily,"Late Wednesday, Vertex Pharmaceuticals reported adjusted earnings of $2.56 per share on $1.52 billion in sales for its first quarter ended March 31. In response, VRTX stock popped.",https://www.investors.com/news/technology/vrtx-stock-vertex-earnings-q1-2020/,0.4019,0.296
VRTX,2020-04-28,Here is Why Growth Investors Should Buy Vertex (VRTX) Now,https://cdn.snapi.dev/images/v1/j/g/biotech39.jpg,Zacks Investment Research,"Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.",https://www.zacks.com/stock/news/894302/here-is-why-growth-investors-should-buy-vertex-vrtx-now,0.3818,0.5719
VRTX,2020-04-28,Why Vertex's Stock Is Trading Lower Today,https://cdn.snapi.dev/images/v1/8/o/microscope-3184432-1920-2.jpg,Benzinga,Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower on Tuesday after getting a downgrade.,https://www.benzinga.com/news/20/04/15897406/why-vertexs-stock-is-trading-lower-today,-0.296,0.0
VRTX,2020-04-28,Why Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season,https://cdn.snapi.dev/images/v1/p/o/biotech22.jpg,Zacks Investment Research,Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,https://www.zacks.com/stock/news/894041/why-vertex-pharmaceuticals-vrtx-might-surprise-this-earnings-season,0.2732,0.7717
VRTX,2020-04-28,5 Top-Ranked Nasdaq Stocks to Buy Ahead of Earnings Results,https://cdn.snapi.dev/images/v1/u/p/etf46-12.jpg,Zacks Investment Research,"Despite the coronavirus-induced economic disaster and stock market turmoil, a handful of Nasdaq stocks are set to beat earnings estimates.",https://www.zacks.com/stock/news/893822/5-top-ranked-nasdaq-stocks-to-buy-ahead-of-earnings-results,0.0,-0.765
VRTX,2020-04-27,Focus on Coronavirus Treatments to Boost Biotech Stocks,https://cdn.snapi.dev/images/v1/s/1/biotech6.jpg,Zacks Investment Research,Focus on Coronavirus Treatments to Boost Biotech Stocks,https://www.zacks.com/commentary/891342/focus-on-coronavirus-treatments-to-boost-biotech-stocks,0.4019,0.4019
VRTX,2020-04-27,Goldman Sachs Says Buy 4 Biotech Stocks in Front of Q1 Earnings,https://cdn.snapi.dev/images/v1/n/f/ww222222-1.jpg,24/7 Wall Street,"In what has become truly the most challenging investing environment in decades, it is probably no surprise to most investors that health care is the top-performing sector this year in the S&P 500.",https://247wallst.com/healthcare-business/2020/04/27/goldman-sachs-says-buy-4-biotech-stocks-in-front-of-q1-earnings/,0.0,0.7841
VRTX,2020-04-24,Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?,https://cdn.snapi.dev/images/v1/u/f/biotech8.jpg,Zacks Investment Research,"On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.",https://www.zacks.com/stock/news/887768/can-vertex-vrtx-withstand-the-coronavirus-impact-on-q1-earnings,0.0,0.0
VRTX,2020-04-22,What's The Best Biotech Stock to Buy for Treating Sickle Cell Disease?,https://cdn.snapi.dev/images/v1/m/o/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5686342fred-blood-cells-abstract-l7suoukjpgw700opresize.jpg,The Motley Fool,Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.,https://www.fool.com/investing/2020/04/22/whats-the-best-biotech-stock-to-buy-for-treating-s.aspx,0.6369,0.0
VRTX,2020-04-16,2 Great Stocks You Can Buy and Hold Forever: CRSP & VRTX,https://cdn.snapi.dev/images/v1/u/e/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5677402fgettyimages-874418372jpgw700opresize.jpg,The Motley Fool,These companies -- an online retailer and a biotech -- have plenty of growth drivers.,https://www.fool.com/investing/2020/04/16/2-great-stocks-you-can-buy-and-hold-forever.aspx,0.6249,0.3818
VRTX,2020-04-15,Should You Buy Biotech Stocks Right Now?,https://cdn.snapi.dev/images/v1/y/1/biotech14.jpg,The Motley Fool,The definitive answer is.,https://www.fool.com/investing/2020/04/15/should-you-buy-biotech-stocks-right-now.aspx,0.0,0.0
VRTX,2020-04-14,Vertex Is Positioned For Upside,https://cdn.snapi.dev/images/v1/n/a/biotech6-2.jpg,Seeking Alpha,Vertex Is Positioned For Upside,https://seekingalpha.com/article/4337510-vertex-is-positioned-for-upside,0.0,0.0
VRTX,2020-04-13,Here Are The Best Large-Cap Stocks To Buy Now,https://cdn.snapi.dev/images/v1/0/x/0x600-446.jpg,Seeking Alpha,"The best large-cap industries are electronic gaming, drugmakers, gold, packaged foods, and healthcare plans.",https://seekingalpha.com/article/4337204-are-best-large-cap-stocks-to-buy-now,0.6369,0.6369
VRTX,2020-04-13,3 Top Biotech Stocks to Buy in April,https://cdn.snapi.dev/images/v1/9/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5671042ftest-tubes-with-green-arrow-pointing-upjpgw700opresize.jpg,The Motley Fool,They're already beating the market. And they still have lots of room to run.,https://www.fool.com/investing/2020/04/12/3-top-biotech-stocks-to-buy-in-april.aspx,0.2023,-0.4588
VRTX,2020-04-10,Where Will Vertex Pharmaceuticals Be in 1 Year?,https://cdn.snapi.dev/images/v1/l/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5672542fgettyimages-910637338jpgw700opresize.jpg,The Motley Fool,"Its newly approved cystic fibrosis treatment, Trikafta, has what it takes to drive revenue growth.",https://www.fool.com/investing/2020/04/10/where-will-vertex-pharmaceuticals-be-in-1-year.aspx,0.0,0.6597
VRTX,2020-04-08,3 Blue-Chip Biotech Stocks Hitting New Highs,https://cdn.snapi.dev/images/v1/o/e/microscope-275984-1920-24.jpg,Investopedia,These strong biotech performers are benefiting from impressive drug pipelines rather than speculation about a virus cure.,https://www.investopedia.com/3-blue-chip-biotech-stocks-hitting-new-highs-4802200,0.0,0.765
VRTX,2020-04-07,Vertex Pharmaceuticals And BioMarin Pharmaceutical: 2 Safe Biotech Picks To Buy During This Bear Market,https://cdn.snapi.dev/images/v1/a/a/biotech2.jpg,Seeking Alpha,Vertex Pharmaceuticals And BioMarin Pharmaceutical: 2 Safe Biotech Picks To Buy During This Bear Market,https://seekingalpha.com/article/4336491-vertex-pharmaceuticals-and-biomarin-pharmaceutical-2-safe-biotech-picks-to-buy-during-this,0.4404,0.4404
VRTX,2020-04-06,"Strong Market Rally: Vertex Tries Breakout; Microsoft, Dexcom Set Up",https://cdn.snapi.dev/images/v1/w/x/images-2.jpg,Investors Business Daily,"Stocks make bullish move: Vertex tries to breakout; Microsoft, Dexcom set up.",https://www.youtube.com/watch?v=usREt7pgBAk,0.5106,0.0
VRTX,2020-04-03,Should I Trade My Growth Stocks for Value Stocks?,https://cdn.snapi.dev/images/v1/j/d/etf-8.jpg,The Motley Fool,Is one of these investing styles preferable to the other in these uncertain times?,https://www.fool.com/investing/2020/04/03/should-i-trade-my-growth-stocks-for-value-stocks.aspx,0.6124,-0.296
VRTX,2020-04-01,Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals,https://cdn.snapi.dev/images/v1/z/l/stocks-to-buy-768x512.jpg,The Motley Fool,One of these biotech stocks holds a monopoly in the market for drugs that treat cystic fibrosis; the other is looking to develop a treatment for COVID-19. Which one is the better buy today?,https://www.fool.com/investing/2020/04/01/better-buy-vertex-pharmaceuticals-vs-regeneron-pha.aspx,0.4404,0.6808
VRTX,2020-04-01,Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?,https://cdn.snapi.dev/images/v1/y/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5657352fgettyimages-859500968jpgw700opresize.jpg,The Motley Fool,Postponed clinical trials might mean a longer time-to-market for certain drugs.,https://www.fool.com/investing/2020/04/01/do-clinical-trial-delays-mean-trouble-for-pharmace.aspx,-0.4019,0.0772
VRTX,2020-03-30,"Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View",https://cdn.snapi.dev/images/v1/g/r/biotech34.jpg,Zacks Investment Research,"Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.",https://www.zacks.com/stock/news/845617/vertex-to-halt-enrollment-due-to-coronavirus-keeps-sales-view,0.0,-0.5859
VRTX,2020-03-30,4 Reasons Drug Stocks Are a Buy Right Now,https://cdn.snapi.dev/images/v1/g/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5656092fgettyimages-1165195324jpgw700opresize.jpg,The Motley Fool,Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19.,https://www.fool.com/investing/2020/03/30/4-reasons-drug-stocks-are-a-buy-right-now.aspx,0.0,0.0
VRTX,2020-03-30,My Top Healthcare Stocks to Buy in the Market Crash,https://cdn.snapi.dev/images/v1/h/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5652342fwooden-blocks-with-healthcare-imagesjpgw700opresize.jpg,The Motley Fool,Profitable. Great revenue and earnings growth.,https://www.fool.com/investing/2020/03/29/my-top-healthcare-stocks-to-buy-in-the-market-cras.aspx,-0.2263,0.8625
VRTX,2020-03-27,Vertex Pharmaceuticals to Pause Some Clinical Trials,https://cdn.snapi.dev/images/v1/j/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5655252fbiohazard-suit-stop-gettyjpgw700opresize.jpg,The Motley Fool,"With the coronavirus pandemic growing rapidly, the company doesn't see drug studies as the best use of healthcare resources right now.",https://www.fool.com/investing/2020/03/27/vertex-pharmaceuticals-to-pause-cystic-fibrosis-tr.aspx,0.0,0.7096
VRTX,2020-03-27,10 Stocks To Buy With Low Debt And High Liquidity,https://cdn.snapi.dev/images/v1/f/o/fod922-5.jpg,Benzinga,"Given the near-term economic uncertainty surrounding the COVID-19 outbreak, investors have been shifting their focus from growth stocks to stocks that have the balance sheets and liquidity to weather the current downturn.",https://www.benzinga.com/general/education/20/03/15675029/10-stocks-to-buy-with-low-debt-and-high-liquidity,-0.5574,0.0516
VRTX,2020-03-26,Stock News: Dow Jones Scores Third Straight Bullish Gain,https://cdn.snapi.dev/images/v1/e/r/ee2d-2.jpg,Investors Business Daily,"Major stock indexes rallied sharply again Thursday, but actionable charts are in short supply.",https://www.youtube.com/watch?v=e-qRhVMUddY,0.6486,0.0
VRTX,2020-03-25,4 Reasons Biotech Stocks Are a Buy Right Now,https://cdn.snapi.dev/images/v1/q/2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5646752fgettyimages-1212296671-1jpgw700opresize.jpg,The Motley Fool,Biotech companies have outperformed the general market -- and there are plenty of reasons to remain optimistic.,https://www.fool.com/investing/2020/03/25/4-reasons-biotech-stocks-are-a-buy-right-now.aspx,0.0,0.3182
VRTX,2020-03-24,3 Stocks to Buy to Make Your Coronavirus Lockdown a Profitable One,https://cdn.snapi.dev/images/v1/u/x/gettyimages-1209679043jpgw711.jpg,The Motley Fool,Stuck at home because of the COVID-19 outbreak? Make money over the long run by investing in these great stocks.,https://www.fool.com/investing/2020/03/24/3-stocks-to-buy-to-make-your-coronavirus-lockdown.aspx,0.4404,0.4767
VRTX,2020-03-23,IBD Stock Of The Day: Why Coronavirus Isn't Slamming This Biotech Leader,https://cdn.snapi.dev/images/v1/2/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5523592f100-bills-magnifying-glass-and-stock-datajpgw700opresize.jpg,Investors Business Daily,Vertex is the IBD Stock Of The Day as VRTX stock parries coronavirus worries on enthusiasm for its new cystic fibrosis treatment. Vertex stock is weathering well in the correction.,https://www.investors.com/news/technology/vrtx-stock-analysts-bullish-biotech-transitions-cystic-fibrosis-treatment/,0.0,0.296
VRTX,2020-03-23,Coronavirus Crisis: 3 Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/x/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5642892ffemale-scientist-holding-2-test-tubesjpgw700opresize.jpg,The Motley Fool,These biotechs' profits shouldn't be dented by the COVID-19 pandemic. And their growth prospects appear to be really good.,https://www.fool.com/investing/2020/03/22/coronavirus-crisis-3-biotech-stocks-to-buy-right-n.aspx,-0.6249,0.8718
VRTX,2020-03-19,Nasdaq Starts New Rally Attempt With Bullish Gain,https://cdn.snapi.dev/images/v1/e/r/ysny27-1.jpg,Investors Business Daily,Some beaten down growth stocks perked up Thursday even as the coronavirus continued to spread.,https://www.youtube.com/watch?v=UpetkJVMtl4,0.5267,-0.0516
VRTX,2020-03-19,"Vertex Confirms 20% Revenue Growth Forecast, Presents A Compelling Investment Opportunity",https://cdn.snapi.dev/images/v1/f/r/biotech27.jpg,Seeking Alpha,"Vertex Confirms 20% Revenue Growth Forecast, Presents A Compelling Investment Opportunity",https://seekingalpha.com/article/4332958-vertex-confirms-20-revenue-growth-forecast-presents-compelling-investment-opportunity,0.743,0.743
VRTX,2020-03-17,"Why Biogen, GW Pharmaceuticals, and Vertex Pharmaceuticals Stocks Jumped Today",https://cdn.snapi.dev/images/v1/a/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5639752ftest-tubes-with-green-arrow-pointing-upjpgw700opresize.jpg,The Motley Fool,A rebounding stock market lifted all three of these biotech stocks.,https://www.fool.com/investing/2020/03/17/timesensitivewhy-biogen-gw-pharmaceuticals-and-ver.aspx,0.0,0.0
VRTX,2020-03-16,4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy,https://cdn.snapi.dev/images/v1/v/i/drugs44.jpg,Zacks Investment Research,Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.,https://www.zacks.com/stock/news/816672/4-big-drug-biotech-stocks-up-in-coronavirus-hit-economy,0.0,-0.25
VRTX,2020-03-16,4 Top Biotech Stocks to Buy in the Time of Coronavirus,https://cdn.snapi.dev/images/v1/q/g/medical13.jpg,Zacks Investment Research,We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.,https://www.zacks.com/stock/news/816652/4-top-biotech-stocks-to-buy-in-the-time-of-coronavirus,0.2023,-0.8957
VRTX,2020-03-16,Pick These 4 Stocks With Impressive Interest Coverage Ratio,https://cdn.snapi.dev/images/v1/9/1/semi9.jpg,Zacks Investment Research,"Debt, which is crucial to financing operations for the majority of companies, comes at a cost called interest. Interest expense has a direct bearing on the profitability of a company.",https://www.zacks.com/stock/news/816647/pick-these-4-stocks-with-impressive-interest-coverage-ratio,0.743,0.6808
VRTX,2020-03-16,"Coronavirus Bear Market: All Stocks Are Under Quarantine, But Keep Vertex, Biogen, Dexcom, Eli Lilly, Masimo Under Observation",https://cdn.snapi.dev/images/v1/c/g/biotech30-2.jpg,Investors Business Daily,"In the coronavirus bear market, all stocks are under quarantine. But keep health care stocks Vertex, Biogen, Dexcom, Eli Lilly, Masimo under observation.",https://www.investors.com/news/coronavirus-bear-market-vertex-biogen-dexcom-eli-lilly-masimo/,0.0,0.4939
VRTX,2020-03-11,3 Charts Suggest Traders Will Remain Bullish on Biotech,https://cdn.snapi.dev/images/v1/b/p/gettyimages-1187891590jpgw600.jpg,Investopedia,The recent drop in the share prices of biotech and related health care companies could present traders with a buying opportunity.,https://www.investopedia.com/3-charts-suggest-traders-will-remain-bullish-on-biotech-4799315,0.0,0.7269
VRTX,2020-03-10,How to Be Greedy When Others Are Fearful,https://cdn.snapi.dev/images/v1/n/x/stocks141-2.jpg,The Motley Fool,Three steps you can take to follow Warren Buffett's advice and achieve extraordinary long-term results.,https://www.fool.com/investing/2020/03/10/how-to-be-greedy-when-others-are-fearful.aspx,-0.6705,0.0
VRTX,2020-03-09,2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market,https://cdn.snapi.dev/images/v1/f/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5613422fgettyimages-645455760jpgw700opresize.jpg,The Motley Fool,"Despite fears of a COVID-19 pandemic, these two stocks are worth considering.",https://www.fool.com/investing/2020/03/07/2-biotech-stocks-to-buy-as-coronavirus-fears-tank.aspx,-0.4215,0.4993
VRTX,2020-03-06,5 Biotech Stocks to Buy for a Strong Growth Prognosis,https://cdn.snapi.dev/images/v1/b/i/biotech1600d-768x432-4.jpg,InvestorPlace,"The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.",https://investorplace.com/2020/03/5-biotech-stocks-to-buy-for-a-strong-growth-prognosis/,0.7096,0.3818
VRTX,2020-03-05,3 Biotech Stocks That Are Coronavirus Safe Havens,https://cdn.snapi.dev/images/v1/5/2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5614122f3-test-tubesjpgw700opresize.jpg,The Motley Fool,These stocks aren't likely to be infected with the current market worries.,https://www.fool.com/investing/2020/03/05/3-biotech-stocks-that-are-coronavirus-safe-havens.aspx,0.4404,-0.7184
VRTX,2020-03-03,5 Top Stocks With Great Earnings Beat Potential,https://cdn.snapi.dev/images/v1/4/t/software14.jpg,Zacks Investment Research,These top-ranked stocks are likely to beat on the bottom line in their next release.,https://www.zacks.com/stock/news/794273/5-top-stocks-with-great-earnings-beat-potential,0.7096,0.0
VRTX,2020-03-03,3 Top Healthcare Stocks to Buy in March,https://cdn.snapi.dev/images/v1/1/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5610372fhealthcare-icons-with-doctor-holding-tabletjpgw700opresize.jpg,The Motley Fool,Looking for great stocks to buy if the market rebounds in a big way? Think healthcare.,https://www.fool.com/investing/2020/03/03/3-top-healthcare-stocks-to-buy-in-march.aspx,0.2023,0.6249
VRTX,2020-03-02,All the Stocks I'm Selling If the Coronavirus Keeps Spreading,https://cdn.snapi.dev/images/v1/9/k/stocks141-2.jpg,The Motley Fool,You'll might want to consider the same approach.,https://www.fool.com/investing/2020/03/01/all-the-stocks-im-selling-if-the-coronavirus-keeps.aspx,0.0,0.0772
VRTX,2020-03-02,Why Is Vertex (VRTX) Down 2.7% Since Last Earnings Report?,https://cdn.snapi.dev/images/v1/g/b/biotech10.jpg,Zacks Investment Research,Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?,https://www.zacks.com/stock/news/790096/why-is-vertex-vrtx-down-27-since-last-earnings-report,0.0,0.0
VRTX,2020-02-24,3 Reasons Why Vertex (VRTX) Is a Great Growth Stock,https://cdn.snapi.dev/images/v1/s/4/biotech33.jpg,Zacks Investment Research,"Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.",https://www.zacks.com/stock/news/781499/3-reasons-why-vertex-vrtx-is-a-great-growth-stock,0.7717,0.7096
VRTX,2020-02-24,Looking for a Growth Stock? Why It is Time to Focus on Vertex (VRTX),https://cdn.snapi.dev/images/v1/m/a/biotech21.jpg,Zacks Investment Research,"If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).",https://www.zacks.com/stock/news/780983/looking-for-a-growth-stock-why-it-is-time-to-focus-on-vertex-vrtx,0.3818,0.5994
VRTX,2020-02-20,Jim Cramer: Experts are calling Vertex Pharmaceuticals the 'most promising story in biotech',https://cdn.snapi.dev/images/v1/h/r/jim-cramer-experts-are-calling-vertex-pharmaceuticals-the-most-promising-story-in-biotech.jpg,CNBC Television,"""As much as I hate to chase, I honestly don't think you're that late to the party with Vertex if you buy it at these levels,"" the ""Mad Money"" host says.",https://www.youtube.com/watch?v=OiU0PesKofc,0.4576,-0.296
VRTX,2020-02-19,Better Buy: Vertex Pharmaceuticals vs. Incyte,https://cdn.snapi.dev/images/v1/m/1/biotech36.jpg,The Motley Fool,Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.,https://www.fool.com/investing/2020/02/19/better-buy-vertex-pharmaceuticals-vs-incyte.aspx,0.4404,0.0
VRTX,2020-02-18,Vertex Energy's Refined Business Model Should Not Be Ignored,https://cdn.snapi.dev/images/v1/g/9/biotech37.jpg,Seeking Alpha,Vertex Energy's Refined Business Model Should Not Be Ignored,https://seekingalpha.com/article/4325021-vertex-energys-refined-business-model-should-not-be-ignored,0.2411,0.2411
VRTX,2020-02-17,3  Best Biotech Stocks to Buy for the Next Decade,https://cdn.snapi.dev/images/v1/b/7/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5577432f3-test-tubesjpgw700opresize.jpg,The Motley Fool,"A large-cap biotech, a mid-cap biotech, and a small-cap biotech that have one thing in common: great growth prospects.",https://www.fool.com/investing/2020/02/16/3-best-biotech-stocks-to-buy-for-the-next-decade.aspx,0.6369,0.836
VRTX,2020-02-14,What's in Store for Vertex in 2020 After a Remarkable 2019?,https://cdn.snapi.dev/images/v1/9/8/biotech28.jpg,Zacks Investment Research,"In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.",https://www.zacks.com/stock/news/765734/whats-in-store-for-vertex-in-2020-after-a-remarkable-2019,0.5574,0.0
VRTX,2020-02-11,Buy These  Five Stocks With Attractive Sales Growth Right Now,https://cdn.snapi.dev/images/v1/m/t/smu5-3.jpg,Zacks Investment Research,"Sales growth is an important metric for any company, as it is a vital part of growth projections and instrumental in strategic decision making.",https://www.zacks.com/stock/news/759778/buy-these-5-stocks-with-attractive-sales-growth-right-now,0.6705,0.802
VRTX,2020-02-07,3 Biotech Companies Analyzed,https://cdn.snapi.dev/images/v1/s/m/hea2.jpg,The Motley Fool,We examine three biotech companies' past performances and future outlooks.,https://www.fool.com/investing/2020/02/07/3-biotech-companies-analyzed.aspx,0.0,0.0
VRTX,2020-02-05,Why Vertex (VRTX) Might be Well Poised for a Surge,https://cdn.snapi.dev/images/v1/q/c/biotech13-2.jpg,Zacks Investment Research,"Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.",https://www.zacks.com/stock/news/750873/why-vertex-vrtx-might-be-well-poised-for-a-surge,0.4767,0.6808
VRTX,2020-02-05,"Vertex (VRTX) Hits 52-Week High, Can the Run Continue?",https://cdn.snapi.dev/images/v1/d/u/biotech37.jpg,Zacks Investment Research,"Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",https://www.zacks.com/stock/news/750430/vertex-vrtx-hits-52-week-high-can-the-run-continue,0.0,0.8121
VRTX,2020-02-03,Vertex Beats: How A High P/E Biotech May Be Undervalued,https://cdn.snapi.dev/images/v1/3/y/biotech29.jpg,Seeking Alpha,Vertex Beats: How A High P/E Biotech May Be Undervalued,https://seekingalpha.com/article/4320927-vertex-beats-how-high-p-e-biotech-may-be-undervalued,0.0,0.0
VRTX,2020-02-03,Where Will Vertex Pharmaceuticals Be in 10 Years?,https://cdn.snapi.dev/images/v1/s/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5553932f2020-with-ladder-to-2030jpgw700opresize.jpg,The Motley Fool,The future looks bright for this big biotech.,https://www.fool.com/investing/2020/02/02/where-will-vertex-pharmaceuticals-be-in-10-years.aspx,0.0,0.4404
VRTX,2020-01-31,Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales,https://cdn.snapi.dev/images/v1/t/n/biotech16.jpg,Zacks Investment Research,Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.,https://www.zacks.com/stock/news/743173/vertex-vrtx-q4-earnings-beat-on-solid-cf-product-sales,0.1531,0.4215
VRTX,2020-01-31,Is Vertex Pharmaceuticals Stock Still a Strong Buy?,https://cdn.snapi.dev/images/v1/j/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5556212fcystic-fibrosisjpgw700opresize.jpg,The Motley Fool,Don't let Vertex's current valuation fool you. This elite biotech stock is a steal at current levels.,https://www.fool.com/investing/2020/01/31/is-vertex-pharmaceuticals-still-a-strong-buy.aspx,0.5106,-0.7269
VRTX,2020-01-31,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeffrey Leiden on Q4 2019 Results - Earnings Call Transcript,https://cdn.snapi.dev/images/v1/a/n/transcript17.jpg,Seeking Alpha,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeffrey Leiden on Q4 2019 Results - Earnings Call Transcript,https://seekingalpha.com/article/4320447-vertex-pharmaceuticals-incorporated-vrtx-ceo-jeffrey-leiden-on-q4-2019-results-earnings-call,0.0,0.0
VRTX,2020-01-30,"Vertex Pharmaceuticals Reports Q4 Financial Earnings, Beats Estimates",https://cdn.snapi.dev/images/v1/n/b/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5555152fgettyimages-1139649025jpgw700opresize.jpg,The Motley Fool,The company outperformed Wall Street expectations thanks to strong results from Trikafta.,https://www.fool.com/investing/2020/01/30/vertex-pharmaceuticals-reports-q4-financial-earnin.aspx,0.0,0.7351
VRTX,2020-01-30,Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates,https://cdn.snapi.dev/images/v1/h/z/biotech38.jpg,Zacks Investment Research,"Vertex (VRTX) delivered earnings and revenue surprises of 40.50% and 41.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?",https://www.zacks.com/stock/news/741421/vertex-pharmaceuticals-vrtx-q4-earnings-and-revenues-top-estimates,0.2023,0.128
VRTX,2020-01-30,"Vertex Pharma stock rises on earnings, outlook beat",https://cdn.snapi.dev/images/v1/i/2/biotech35.jpg,Market Watch,"Vertex Pharmaceuticals Inc. VRTX, -0.90% shares rose in the extended session Thursday after the biotech drug maker's results and forecast topped Wall Street estimates.",https://www.marketwatch.com/story/vertex-pharma-stock-rises-on-earnings-outlook-beat-2020-01-30,0.0,0.296
VRTX,2020-01-30,Top Biotech Vertex Pops After Crushing Fourth-Quarter Expectations,https://cdn.snapi.dev/images/v1/7/l/biotech36.jpg,Investors Business Daily,"Late Thursday, Vertex Pharmaceuticals reported adjusted income of $1.70 per share on $1.41 billion in revenue for its fourth quarter ended Dec. 31. As a result, VRTX stock popped.",https://www.investors.com/news/technology/vrtx-stock-vertex-pharmaceuticals-earnings-q4-2019/,-0.1779,0.296
VRTX,2020-01-29,"Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More",https://cdn.snapi.dev/images/v1/t/8/biotech31.jpg,Zacks Investment Research,Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.,https://www.zacks.com/stock/news/738675/big-drug-biotech-stock-earnings-on-jan-30-biib-alxn-more,0.0,0.0
VRTX,2020-01-29,Why Vertex (VRTX) Might Surprise This Earnings Season,https://cdn.snapi.dev/images/v1/y/m/biotech30.jpg,Zacks Investment Research,Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.,https://www.zacks.com/stock/news/738631/why-vertex-vrtx-might-surprise-this-earnings-season,0.2732,0.7717
VRTX,2020-01-28,Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?,https://cdn.snapi.dev/images/v1/f/5/biotech14.jpg,Zacks Investment Research,"On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.",https://www.zacks.com/stock/news/736752/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q4-earnings,0.3818,0.0
VRTX,2020-01-27,3 Biotech Start-Ups That Could Soar in 2020,https://cdn.snapi.dev/images/v1/y/w/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5525582fmoney-in-a-beaker-gettyjpgw700opresize.jpg,The Motley Fool,Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.,https://www.fool.com/investing/2020/01/27/3-biotech-start-ups-that-could-soar-in-2020.aspx,0.0,0.0
VRTX,2020-01-27,Vertex's $950 Million Bet That Could Pay Off Big-Time for Investors,https://cdn.snapi.dev/images/v1/5/g/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5544452ftype-1-diabetesjpgw700opresize.jpg,The Motley Fool,The big biotech thinks it just might be able to cure type 1 diabetes.,https://www.fool.com/investing/2020/01/26/vertexs-950-million-bet-that-could-pay-off-big-tim.aspx,-0.1027,0.0
VRTX,2020-01-27,Better Buy:  Vertex Pharmaceuticals vs. Galapagos,https://cdn.snapi.dev/images/v1/a/1/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5543462fgloved-hands-holding-2-test-tubesjpgw700opresize.jpg,The Motley Fool,One of these biotechs dominates the treatment of cystic fibrosis. The other doesn't have a single FDA-approved drug -- yet.,https://www.fool.com/investing/2020/01/25/better-buy-vertex-pharmaceuticals-vs-galapagos.aspx,0.4404,0.0516
VRTX,2020-01-23,Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?,https://cdn.snapi.dev/images/v1/i/n/biotech1.jpg,Zacks Investment Research,Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://www.zacks.com/stock/news/730721/vertex-pharmaceuticals-vrtx-expected-to-beat-earnings-estimates-should-you-buy,0.0,0.2263
VRTX,2020-01-23,Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again,https://cdn.snapi.dev/images/v1/i/v/biotech39.jpg,Zacks Investment Research,Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://www.zacks.com/stock/news/730686/why-vertex-vrtx-is-poised-to-beat-earnings-estimates-again,0.25,0.6597
VRTX,2020-01-23,2 Ultra-Expensive Biotech Stocks Still Worth Buying,https://cdn.snapi.dev/images/v1/2/3/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5544032fmoney-seriesjpgw700opresize.jpg,The Motley Fool,BeiGene and Vertex Pharmaceuticals aren't nearly as expensive as you may think.,https://www.fool.com/investing/2020/01/23/2-ultra-expensive-biotech-stocks-still-worth-buyin.aspx,0.2263,0.0
VRTX,2020-01-15,Are Biotech Stocks Due for a Correction in 2020?,https://cdn.snapi.dev/images/v1/6/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5532132fpeople-working-in-a-labjpgw700opresize.jpg,The Motley Fool,Shares of these biotech companies are near their five-year highs after some strong performances in 2019.,https://www.fool.com/investing/2020/01/15/are-biotech-stocks-due-for-a-correction-in-2020.aspx,0.0,0.6705
VRTX,2020-01-13,"Vertex, Dexcom, Insulet, Intuitive Surgical In Buy Range Before Healthcare Conference",https://cdn.snapi.dev/images/v1/w/f/medical17.jpg,Investors Business Daily,"Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference.",https://www.investors.com/news/vertex-stock-intuitive-surgical-dexcom-insulet-in-buy-range-before-jpmorgan-healthcare-conference/,0.0,0.0
VRTX,2020-01-10,"Nasdaq Hits High; Leaderboard’s Dexcom, Vertex, Lululemon In Buy Zones",https://cdn.snapi.dev/images/v1/z/i/etf26.jpg,Investors Business Daily,"Nasdaq hits new high; Leaderboard stocks Dexcom, Vertex, Lululemon in buy zones.",https://www.youtube.com/watch?v=JPhI1YM1Bak,0.0,0.0
VRTX,2020-01-09,Why Your 2020 Resolution Should Be to Buy More Healthcare Stocks,https://cdn.snapi.dev/images/v1/a/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5526872f2020-with-0s-formed-by-heart-and-a-stethoscopejpgw700opresize.jpg,The Motley Fool,Here are three compelling reasons to buy healthcare stocks this year.,https://www.fool.com/investing/2020/01/09/why-your-2020-resolution-should-be-to-buy-more-hea.aspx,0.0,0.2263
VRTX,2020-01-08,Why Has Vertex Pharmaceuticals’ Stock Gained 30% In The Last Quarter?,https://cdn.snapi.dev/images/v1/e/m/why-has-vertex-pharmaceuticals-stock-gained-30-in-the-last-quarter.jpg,Forbes,"Vertex Pharmaceuticals is a bio-pharmaceutical company based in Boston, U.S. The company is one of the first bio-pharma companies that uses rational drug design, whereby its drug molecule is complementary in shape and charge to the biochemical target.",https://www.forbes.com/sites/greatspeculations/2020/01/08/why-has-vertex-pharmaceuticals-stock-gained-30-in-the-last-quarter/,0.3818,0.0
VRTX,2020-01-07,Vertex Pharmaceuticals (VRTX) Stock Moves -0.11%: What You Should Know,https://cdn.snapi.dev/images/v1/9/2/biotech21.jpg,Zacks Investment Research,"Vertex Pharmaceuticals (VRTX) closed at $223.79 in the latest trading session, marking a -0.11% move from the prior day.",https://www.zacks.com/stock/news/707024/vertex-pharmaceuticals-vrtx-stock-moves-011-what-you-should-know,0.0,0.0
VRTX,2020-01-06,3 High-Growth Stocks That Can Soar,https://cdn.snapi.dev/images/v1/q/o/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5521902fgettyimages-1086296760jpgw700opresize.jpg,The Motley Fool,Exponential growth is on the horizon for these companies. Investors should take note.,https://www.fool.com/investing/2020/01/06/3-high-growth-stocks-that-can-soar.aspx,0.0,0.3818
VRTX,2020-01-06,10 Stocks With the Highest Sales Growth in 2020 According to Goldman,https://cdn.snapi.dev/images/v1/i/m/images-4.jpg,Investopedia,"For investors seeking stocks than can beat the market in 2020, Goldman Sachs has identified those with the highest projected sales growth.",https://www.investopedia.com/10-stocks-with-the-highest-sales-growth-in-2020-according-to-goldman-4780442,0.3818,0.3818
VRTX,2020-01-06,Is Vertex Pharmaceuticals  Stock a Buy?,https://cdn.snapi.dev/images/v1/9/a/vertex.jpg,The Motley Fool,What does the future hold for this high-flying biotechnology company?,https://www.fool.com/investing/2020/01/04/is-vertex-pharmaceuticals-a-buy.aspx,0.0,0.0
VRTX,2020-01-03,Down Session For Stocks Has Several Bright Spots,https://cdn.snapi.dev/images/v1/s/t/stm8-4.jpg,Investors Business Daily,"Sellers came into the stock market Friday, but leading growth stocks showed underlying strength.",https://www.youtube.com/watch?v=xhVdXcYrIzg,0.4404,0.8271
VRTX,2020-01-03,7 Hot Drug Stocks To Buy In 2020,https://cdn.snapi.dev/images/v1/7/-/7-hot-drug-stocks-to-buy-in-2020.jpg,Forbes,"Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology space.",https://www.forbes.com/sites/moneyshow/2020/01/03/7-hot-drug-stocks-to-buy-in-2020/,0.0,0.7003
VRTX,2019-12-30,Jefferies: Less urgency to get legislation passed in 2020,https://cdn.snapi.dev/images/v1/m/q/jefferies-less-urgency-to-get-legislation-passed-in-2020.jpg,CNBC Television,"Michael Yee, Jefferies analyst, discusses his outlook on biotech companies on CNBC's ""Closing Bell.""",https://www.youtube.com/watch?v=c8TXPRvZzac,0.0,0.0
VRTX,2019-12-30,5 Stocks to Buy in January,https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5520292fa-rising-stack-of-coins-next-to-a-chart-of-yearsjpgw700opresize.jpg,The Motley Fool,"While the stock market is coming off its best year in more than two decades, we still see some good stocks to buy this January. Topping our list are a virtual search engine, biotech giant, Internet of Things (IoT) supplier, fitness company, and pipeline behemoth.",https://www.fool.com/investing/2019/12/30/5-stocks-to-buy-in-january.aspx,0.0,0.8481
VRTX,2019-12-30,The 3 Best Healthcare Stocks to Buy for 2020,https://cdn.snapi.dev/images/v1/z/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5518912f2020-with-0s-formed-by-heart-and-a-stethoscopejpgw700opresize.jpg,The Motley Fool,These three healthcare stocks have all the ingredients needed to cook up great returns in the new year.,https://www.fool.com/investing/2019/12/29/the-3-best-healthcare-stocks-to-buy-for-2020.aspx,0.6369,0.6249
VRTX,2019-12-30,"20 Great Stock Ideas For 2020, From The Best Fund Managers",https://cdn.snapi.dev/images/v1/p/u/20-great-stock-ideas-for-2020-from-the-best-fund-managers.jpg,Forbes,"Top stock picks for 2020, according to the best portfolio managers.",https://www.forbes.com/sites/sergeiklebnikov/2020/12/29/20-great-stock-ideas-for-2020-from-the-best-fund-managers/,0.8519,0.7184
VRTX,2019-12-27,Inphi And Vertex Flatten Out; Incyte Gets Support,https://cdn.snapi.dev/images/v1/s/t/stocks2-4.jpg,Investors Business Daily,Markets Take A Pause; Stock Setups Continue.,https://www.youtube.com/watch?v=EeD1FvAQRg0,0.4019,0.0
VRTX,2019-12-19,Biotech Stock Outlook: M&A Activity Retains Growth Streak,https://cdn.snapi.dev/images/v1/w/o/biotech29.jpg,Zacks Investment Research,Biotech Stock Outlook: M&A Activity Retains Growth Streak,https://www.zacks.com/commentary/678203/biotech-stock-outlook-ma-activity-retains-growth-streak,0.3818,0.3818
VRTX,2019-12-18,Better Buy:  Vertex Pharmaceuticals vs.  Alexion Pharmaceuticals,https://cdn.snapi.dev/images/v1/x/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5510712fgettyimages-1010214820jpgw700opresize.jpg,The Motley Fool,"Both of these drugmakers have solid portfolios and treatment pipelines, but savvy investors will find good reason to favor one over the other.",https://www.fool.com/investing/2019/12/18/better-buy-vertex-pharma-vs-alexion-pharma.aspx,0.4404,0.8271
VRTX,2019-12-17,8 Biotech Stocks Morgan Stanley Recommends For 2020,https://cdn.snapi.dev/images/v1/l/a/lab-217041-1280-2-6.jpg,Benzinga,"Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.",https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15004313/8-biotech-stocks-morgan-stanley-recommends-for-2020,0.2263,0.0
VRTX,2019-12-11,Vertex's Kalydeco Gets EU Approval to Treat CF in Infants,https://cdn.snapi.dev/images/v1/2/k/biotech9.jpg,Zacks Investment Research,Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.,https://www.zacks.com/stock/news/665846/vertexs-kalydeco-gets-eu-approval-to-treat-cf-in-infants,0.7003,0.34
VRTX,2019-12-11,Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice,https://cdn.snapi.dev/images/v1/h/k/biotech8.jpg,Zacks Investment Research,"Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.",https://www.zacks.com/stock/news/665732/looking-for-a-growth-stock-3-reasons-why-vertex-vrtx-is-a-solid-choice,0.4939,0.7096
VRTX,2019-12-10,5 Defensive Stocks to Buy as Volatility Index Soars,https://cdn.snapi.dev/images/v1/w/r/ee2d-2.jpg,Zacks Investment Research,"On Dec 9, the fear gauge jumped 16% as uncertainties in the closure of U.S.-China trade deal instilled fear in investors.",https://www.zacks.com/stock/news/663610/5-defensive-stocks-to-buy-as-volatility-index-soars,0.0258,-0.8316
VRTX,2019-12-09,9 Most Overbought Stocks In The S&P 500,https://cdn.snapi.dev/images/v1/j/a/chart-1905225-1920-38.jpg,Benzinga,"While value investors look for stocks that have become priced too low or high based on fundamental metrics such as earnings, revenue and debt, technical traders base their buys and sells off of recent trading action in a stock’s charts.",https://www.benzinga.com/general/education/19/12/14954723/9-most-overbought-stocks-in-the-s-p-500,0.0,-0.296
VRTX,2019-12-09,3 Top Healthcare Stocks to Buy in December,https://cdn.snapi.dev/images/v1/o/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5500542fhealthcare-icons-with-doctor-holding-tabletjpgw700opresize.jpg,The Motley Fool,They dominate their respective markets. And they have fantastic growth prospects.,https://www.fool.com/investing/2019/12/08/3-top-healthcare-stocks-to-buy-in-december.aspx,0.2023,0.8658
VRTX,2019-12-06,Three Stocks from the Zacks #1 Rank Uptrends Screen,https://cdn.snapi.dev/images/v1/v/f/etf25-31.jpg,Zacks Investment Research,Three Stocks from the Zacks #1 Rank Uptrends Screen,https://www.zacks.com/commentary/656737/three-stocks-from-the-zacks-1-rank-uptrends-screen,0.0,0.0
VRTX,2019-12-05,Gene Therapy the Next Best Thing: Here's Why (Revised),https://cdn.snapi.dev/images/v1/a/k/biotech2.jpg,Zacks Investment Research,"Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.",https://www.zacks.com/stock/news/655272/gene-therapy-the-next-best-thing-heres-why-revised,0.6369,0.7184
VRTX,2019-12-04,Gene Therapy the Next Best Thing: Here's Why,https://cdn.snapi.dev/images/v1/7/3/biotech22.jpg,Zacks Investment Research,"Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.",https://www.zacks.com/stock/news/654120/gene-therapy-the-next-best-thing-heres-why,0.6369,0.7184
VRTX,2019-12-04,Here's Why Vertex Pharmaceuticals Rose 13.4% in November,https://cdn.snapi.dev/images/v1/t/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5498442fpaper-airplanes-risingjpgw700opresize.jpg,The Motley Fool,The rare-disease specialist is putting together a respectable end-of-year run.,https://www.fool.com/investing/2019/12/04/heres-why-vertex-pharmaceuticals-rose-134-in-novem.aspx,0.0,0.4404
VRTX,2019-12-03,Why You Should Keep An Eye On These 5 Leading Health Care Stocks,https://cdn.snapi.dev/images/v1/b/i/biotech40.jpg,Investors Business Daily,The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.,https://www.investors.com/news/technology/health-care-stocks-buy-watch/,0.4939,0.9538
VRTX,2019-12-02,Looking For Growth? Take A Look At These Biotechnology Stocks,https://cdn.snapi.dev/images/v1/0/9/092314-0028-nvsholdwith1.jpg,Investors Business Daily,"The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
The post Looking For Growth?",https://www.investors.com/news/technology/biotech-stocks-best-biotech-companies-to-invest-in/,0.3818,0.9136
VRTX,2019-12-02,3 Top Biotech Stocks to Buy in December,https://cdn.snapi.dev/images/v1/5/o/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5493772f3-test-tubes-2fommybjpgw700opresize.jpg,The Motley Fool,"These biotech stocks cover all the bases, from great dividends to promising pipelines.",https://www.fool.com/investing/2019/12/01/3-top-biotech-stocks-to-buy-in-december.aspx,0.2023,0.7783
VRTX,2019-11-29,5 New Drug Approvals the FDA Gave Top Priority,https://cdn.snapi.dev/images/v1/v/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5491932fman-holding-fda-blocks-gettyjpgw700opresize.jpg,The Motley Fool,Here's why the FDA recently approved five new drugs way ahead of schedule.,https://www.fool.com/investing/2019/11/29/5-new-drug-approvals-the-fda-gave-top-priority.aspx,0.2023,0.4215
VRTX,2019-11-27,Report: Vertex Railcar Owes Nearly $45.4 Million,https://cdn.snapi.dev/images/v1/x/t/rails-3309912-1920-82.jpg,Benzinga,FreightWaves occasionally posts high-quality content from partner publications in the freight industry.,https://www.benzinga.com/news/19/11/14896944/report-vertex-railcar-owes-nearly-45-4-million,0.0,0.0
VRTX,2019-11-26,Why Biotech ETFs Surged in Monday's Trading Session,https://cdn.snapi.dev/images/v1/1/1/1149.jpg,Zacks Investment Research,"Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.",https://www.zacks.com/stock/news/642212/why-biotech-etfs-surged-in-mondays-trading-session,0.0,0.6808
VRTX,2019-11-26,Vertex Pharma Shares Are Surging with Huge Demand,https://cdn.snapi.dev/images/v1/d/5/biotech35.jpg,Investopedia,Strong fundamentals alongside big money buy signals suggest additional upside potential for Vertex Pharmaceuticals stock.,https://www.investopedia.com/vertex-pharma-shares-are-surging-with-huge-demand-4777367,0.4588,0.5106
VRTX,2019-11-26,4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal,https://cdn.snapi.dev/images/v1/9/5/952.jpg,Zacks Investment Research,Here are four stocks that boast promising prospects and are most likely to be takeout targets.,https://www.zacks.com/stock/news/638202/4-big-drug-stocks-ripe-for-takeover-after-nvs-mdco-deal,0.0,0.5994
VRTX,2019-11-25,Biotech Stocks Awaken From Long Slumber,https://cdn.snapi.dev/images/v1/e/t/etf33.jpg,Investopedia,Biotech stocks have joined the fourth quarter rally and could post strong gains in the coming months.,https://www.investopedia.com/biotech-stocks-awaken-from-long-slumber-4777209,0.0,0.6908
VRTX,2019-11-25,3 Top Healthcare Stocks to Buy Now,https://cdn.snapi.dev/images/v1/5/g/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5487632fdoctor-with-stethescope-and-healthcare-imagesjpgw700opresize.jpg,The Motley Fool,These stocks are in the right place at the right time.,https://www.fool.com/investing/2019/11/24/3-top-healthcare-stocks-to-buy-now.aspx,0.2023,0.0
VRTX,2019-11-21,Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi,https://cdn.snapi.dev/images/v1/x/x/biotech5.jpg,Zacks Investment Research,The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.,https://www.zacks.com/stock/news/631140/vertex-vrtx-gets-french-reimbursement-for-cf-drug-orkambi,0.0,0.0
VRTX,2019-11-21,"Vertex Pharmaceuticals Shares March Higher, Can It Continue?",https://cdn.snapi.dev/images/v1/s/g/biotech36.jpg,Zacks Investment Research,"As of late, it has definitely been a great time to be an investor Vertex Pharmaceuticals.",https://www.zacks.com/stock/news/630743/vertex-pharmaceuticals-shares-march-higher-can-it-continue,0.296,0.7783
VRTX,2019-11-20,Check Out These 5 Fast-Growing Stocks to Buy,https://cdn.snapi.dev/images/v1/a/s/asset-management40.jpg,InvestorPlace,"Growth is on a different track now, and here are some great ideas for stocks to buy to ride the momentum.",https://investorplace.com/2019/11/7-fast-growing-stocks-to-buy-today/,0.0,0.7717
VRTX,2019-11-20,"Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data",https://cdn.snapi.dev/images/v1/k/w/biotech15.jpg,Zacks Investment Research,Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.,https://www.zacks.com/stock/news/629127/vertex-crisprs-gene-editing-drug-shows-positive-early-data,0.5574,0.5574
VRTX,2019-11-19,4 Big Biotech Stocks Worth Considering Post Q3 Earnings,https://cdn.snapi.dev/images/v1/9/7/973.jpg,Zacks Investment Research,"We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.",https://www.zacks.com/stock/news/627538/4-big-biotech-stocks-worth-considering-post-q3-earnings,0.2263,0.7003
VRTX,2019-11-18,Vertex Pharmaceuticals Is A Strong Buy,https://cdn.snapi.dev/images/v1/q/x/biotech10.jpg,Seeking Alpha,Vertex Pharmaceuticals Is A Strong Buy,https://seekingalpha.com/article/4307551-vertex-pharmaceuticals-strong-buy,0.5106,0.5106
VRTX,2019-11-18,"Drug Approvals, Upbeat Earnings Help Vertex Pharmaceuticals’ Stock Jump 20% In A Month",https://cdn.snapi.dev/images/v1/x/c/biotech3.jpg,Forbes,"Vertex Pharmaceuticals (NASDAQ: VRTX) is an American biopharmaceutical company mainly focused on developing and commercializing therapies for the treatment of cystic fibrosis. Vertex has seen its stock price rise 15% over the last month, driven in part by the U.S.",https://www.forbes.com/sites/greatspeculations/2019/11/18/drug-approvals-upbeat-earnings-help-vertex-pharmaceuticals-stock-jump-20-in-a-month/,0.4019,0.3818
VRTX,2019-11-18,Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants,https://cdn.snapi.dev/images/v1/b/s/press1.jpg,GlobeNewsWire,"-Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales-",https://www.globenewswire.com/news-release/2019/11/18/1948581/0/en/Vertex-and-Molecular-Templates-Establish-Collaboration-to-Discover-and-Develop-Novel-Targeted-Conditioning-Regimens-to-Enhance-Hematopoietic-Stem-Cell-Transplants.html,0.3182,0.0
VRTX,2019-11-18,The Best Biotech Stock to Buy Right Now,https://cdn.snapi.dev/images/v1/l/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5477882fscientist-holding-test-tubejpgw700opresize.jpg,The Motley Fool,This biotech checks off all the boxes.,https://www.fool.com/investing/2019/11/17/the-best-biotech-stock-to-buy-right-now.aspx,0.6369,0.0
VRTX,2019-11-15,Earnings Estimates Rising for Vertex (VRTX): Will It Gain?,https://cdn.snapi.dev/images/v1/d/x/biotech27.jpg,Zacks Investment Research,"Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.",https://www.zacks.com/stock/news/621508/earnings-estimates-rising-for-vertex-vrtx-will-it-gain,0.5267,0.6808
VRTX,2019-11-13,Join The Vertex Energy Journey,https://cdn.snapi.dev/images/v1/k/6/biotech3.jpg,Seeking Alpha,Join The Vertex Energy Journey,https://seekingalpha.com/article/4306281-join-vertex-energy-journey,0.5106,0.5106
VRTX,2019-11-11,Vertex: A Crown Jewel Of Biotech,https://cdn.snapi.dev/images/v1/j/n/biotech40.jpg,Seeking Alpha,Vertex: A Crown Jewel Of Biotech,https://seekingalpha.com/article/4305310-vertex-crown-jewel-biotech,0.3612,0.3612
VRTX,2019-11-11,3 Top Stocks to Buy in November,https://cdn.snapi.dev/images/v1/v/f/software21.jpg,The Motley Fool,They're leaders in their respective markets. And those markets are growing fast.,https://www.fool.com/investing/2019/11/10/3-top-stocks-to-buy-in-november.aspx,0.2023,0.5423
VRTX,2019-11-08,"Vertex Energy, Inc. (VTNR) CEO Benjamin Cowart on Q3 2019 Results - Earnings Call Transcript",https://cdn.snapi.dev/images/v1/x/c/transcript25.jpg,Seeking Alpha,"Vertex Energy, Inc. (VTNR) CEO Benjamin Cowart on Q3 2019 Results - Earnings Call Transcript",https://seekingalpha.com/article/4304484-vertex-energy-inc-vtnr-ceo-benjamin-cowart-q3-2019-results-earnings-call-transcript,0.2732,0.2732
VRTX,2019-11-08,Moving Average Crossover Alert: Vertex Pharmaceuticals,https://cdn.snapi.dev/images/v1/b/k/biotech20.jpg,Zacks Investment Research,"Vertex Pharmaceuticals is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.",https://www.zacks.com/stock/news/610009/moving-average-crossover-alert-vertex-pharmaceuticals,0.296,0.8074
VRTX,2019-11-06,Why the Opioid Crisis Makes Vertex Pharmaceuticals a Buy,https://cdn.snapi.dev/images/v1/h/4/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5462122fgettyimages-1013497338jpgw700opresize.jpg,The Motley Fool,This biotech stock gives investors upside to cutting-edge non-opioid pain management with a trusty revenue stream from its legacy suite of treatments for cystic fibrosis.,https://www.fool.com/investing/2019/11/06/why-the-opioid-crisis-makes-vertex-pharmaceuticals.aspx,-0.6249,-0.0258
VRTX,2019-10-31,"Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates",https://cdn.snapi.dev/images/v1/o/l/biotech5.jpg,Zacks Investment Research,"Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.",https://www.zacks.com/stock/news/596693/vertex-vrtx-q3-earnings-beat-revenues-lag-estimates,-0.34,0.4215
VRTX,2019-10-31,Vertex Pharmaceuticals Posts Strong 3rd-Quarter Revenue Growth,https://cdn.snapi.dev/images/v1/o/b/biotech13.jpg,GuruFocus,Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its third quarter results after the closing bell on Wednesday.,https://www.gurufocus.com/news/973374/vertex-pharmaceuticals-posts-strong-3rdquarter-revenue-growth-,0.7096,0.0
VRTX,2019-10-31,2 Top Healthcare Stocks Every Investor Should Own,https://cdn.snapi.dev/images/v1/l/t/hea2.jpg,The Motley Fool,These titans of the healthcare sector sport virtual monopolies in their core markets.,https://www.fool.com/investing/2019/10/31/2-top-healthcare-stocks-every-investor-should-own.aspx,0.2023,0.0
VRTX,2019-10-31,Will Vertex Pharmaceuticals Continue to Surge Higher?,https://cdn.snapi.dev/images/v1/f/d/biotech9.jpg,Zacks Investment Research,"As of late, it has definitely been a great time to be an investor Vertex Pharmaceuticals.",https://www.zacks.com/stock/news/594788/will-vertex-pharmaceuticals-continue-to-surge-higher,0.0,0.7783
VRTX,2019-10-30,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q3 2019 Results - Earnings Call Transcript,https://cdn.snapi.dev/images/v1/j/r/transcript12.jpg,Seeking Alpha,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q3 2019 Results - Earnings Call Transcript,https://seekingalpha.com/article/4300728-vertex-pharmaceuticals-incorporated-vrtx-ceo-jeff-leiden-q3-2019-results-earnings-call,0.0,0.0
VRTX,2019-10-30,Vertex Pharmaceuticals (VRTX) Beats Q3 Earnings Estimates,https://cdn.snapi.dev/images/v1/x/l/biotech35.jpg,Zacks Investment Research,"Vertex (VRTX) delivered earnings and revenue surprises of 7.89% and -0.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?",https://www.zacks.com/stock/news/593902/vertex-pharmaceuticals-vrtx-beats-q3-earnings-estimates,0.0,0.128
VRTX,2019-10-30,The Top-Rated Biotech Stock Just Reported A Mixed Third Quarter,https://cdn.snapi.dev/images/v1/b/i/biotech40.jpg,Investors Business Daily,"Vertex earnings of $1.23 per share, minus some items, beat estimates Wednesday. But $949.8 million in sales lagged narrowly.",https://www.investors.com/news/technology/vertex-stock-vertex-earnings-q3-2019/,0.0,0.0
VRTX,2019-10-29,Vertex Energy (VTNR) to Report Q3 Results: Wall Street Expects Earnings Growth,https://cdn.snapi.dev/images/v1/z/5/biotech16.jpg,Zacks Investment Research,Vertex Energy (VTNR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://www.zacks.com/stock/news/590631/vertex-energy-vtnr-to-report-q3-results-wall-street-expects-earnings-growth,0.5719,0.4588
VRTX,2019-10-29,Looking for an Earnings Beat? 5 Top Picks,https://cdn.snapi.dev/images/v1/6/5/software31.jpg,Zacks Investment Research,5 top-ranked stocks likely to beat on earnings are great investment picks for stellar gains.,https://www.zacks.com/stock/news/590387/looking-for-an-earnings-beat-5-top-picks,0.2023,0.7579
VRTX,2019-10-28,Vertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug,https://cdn.snapi.dev/images/v1/o/h/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5435282fgettyimages-1137042463jpgw700opresize.jpg,The Motley Fool,What should investors think of this piece of news?,https://www.fool.com/investing/2019/10/28/vertex-pharmaceuticals-gains-fda-approval-for-cyst.aspx,0.6705,0.0
VRTX,2019-10-28,"Google, Facebook, AMD Lead 5 Large-Cap Stocks Near Buy Points With Earnings Due",https://cdn.snapi.dev/images/v1/2/3/23insdp-1.jpg,Investors Business Daily,"Google, Facebook, AMD, Mastercard and Vertex Pharmaceuticals are large caps near buy points. All five have earnings this coming week.",https://www.investors.com/news/google-stock-facebook-stock-amd-stock-near-buy-points/,0.0,0.0
VRTX,2019-10-25,Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?,https://cdn.snapi.dev/images/v1/j/e/biotech18.jpg,Zacks Investment Research,"During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.",https://www.zacks.com/stock/news/584435/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q3-earnings,0.3818,0.4767
VRTX,2019-10-25,Top Ranked Momentum Stocks to Buy for October 25th,https://cdn.snapi.dev/images/v1/a/s/asset-management35.jpg,Zacks Investment Research,Top Ranked Momentum Stocks to Buy for October 25th,https://www.zacks.com/commentary/583858/top-ranked-momentum-stocks-to-buy-for-october-25th,0.2023,0.2023
VRTX,2019-10-25,5 Top Volatility-Defying S&P 500 Stocks of Past Month,https://cdn.snapi.dev/images/v1/t/x/etf35-8.jpg,Zacks Investment Research,"Year to date, the benchmark S&P 500 Index has rallied 20.1%, an impressive performance after a disappointing 2018, when it lost 6.6%.",https://www.zacks.com/stock/news/583800/5-top-volatility-defying-sp-500-stocks-of-past-month,0.2023,-0.296
VRTX,2019-10-25,2 Things Just Happened That Make Vertex Pharmaceuticals Stock a Screaming Buy,https://cdn.snapi.dev/images/v1/y/p/biotechmsn.jpg,The Motley Fool,It's been a big week for this fast-growing biotech.,https://www.fool.com/investing/2019/10/25/2-things-just-happened-that-make-vertex-pharmaceut.aspx,-0.3818,0.0
VRTX,2019-10-24,5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3,https://cdn.snapi.dev/images/v1/e/a/drugs6.jpg,Zacks Investment Research,Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.,https://www.zacks.com/stock/news/582314/5-drug-biotech-stocks-likely-to-surpass-on-earnings-in-q3,0.0,0.25
VRTX,2019-10-22,"Medicals Lead, Growth Hurt: New Oriental, Visa, United Tech, Vertex",https://cdn.snapi.dev/images/v1/v/b/stock-exchange-1376107-960-720-136.jpeg,Investors Business Daily,"Medicals lead, growth stocks hurt: New Oriental, Visa, United Tech, Vertex move.",https://www.youtube.com/watch?v=B71tZyk-Z1A,0.25,0.25
VRTX,2019-10-22,5 Healthcare Stocks to Buy,https://cdn.snapi.dev/images/v1/h/e/healthcare1600a-768x432.jpg,InvestorPlace,"Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.",https://investorplace.com/2019/10/5-healthcare-stocks-to-buy-2/,0.0,0.7184
VRTX,2019-10-22,Vertex Shares Are Rallying: What You Need To Know,https://cdn.snapi.dev/images/v1/5/v/anatomical-2261006-1920-12.jpg,Benzinga,"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares were off to a flying start Tuesday, extending the late-session surge from Monday that followed a positive FDA verdict.",https://www.benzinga.com/general/biotech/19/10/14636557/vertex-shares-are-rallying-what-you-need-to-know,0.296,0.7506
VRTX,2019-10-22,Vertex Stock Jumps After Highly Anticipated CF Drug Gains Approval,https://cdn.snapi.dev/images/v1/5/i/biotech15.jpg,Investors Business Daily,"Shares of Vertex Pharmaceuticals jumped in higher-than-average volume early Tuesday after the biotech company gained FDA approval for a highly anticipated cystic fibrosis treatment.
The post Vertex Stock Jumps After Highly Anticipated CF Drug Gains Approval appeared first on Investor's Business Daily.",https://www.investors.com/news/technology/vertex-stock-jumps-biotech-company-fda-nod-cystic-fibrosis-treatment/,0.6705,0.9081
VRTX,2019-10-21,5 Large-Cap Stocks Set to Beat Earnings Estimates This Month,https://cdn.snapi.dev/images/v1/3/6/363.jpg,Zacks Investment Research,"Third-quarter 2019 earnings results so far are not as disappointing as expected initially. However, the forecast of overall earnings dip in the third quarter is still looming large.",https://www.zacks.com/stock/news/575128/5-large-cap-stocks-set-to-beat-earnings-estimates-this-month,0.0,0.2796
VRTX,2019-10-17,2 High-Growth Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/x/7/ees23.jpg,The Motley Fool,BioMarin Pharmaceutical and Vertex Pharmaceuticals should prove to be outstanding growth vehicles in 2020 and beyond.,https://www.fool.com/investing/2019/10/17/2-high-growth-stocks-to-buy-right-now.aspx,0.0,0.765
VRTX,2019-10-16,Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?,https://cdn.snapi.dev/images/v1/j/g/biotech11.jpg,Zacks Investment Research,Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://www.zacks.com/stock/news/567556/vertex-pharmaceuticals-vrtx-earnings-expected-to-grow-should-you-buy,0.0,0.2263
VRTX,2019-10-14,Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?,https://cdn.snapi.dev/images/v1/m/c/biotech21.jpg,Zacks Investment Research,Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://www.zacks.com/stock/news/563648/can-vertex-vrtx-keep-the-earnings-surprise-streak-alive,0.5719,0.6597
VRTX,2019-10-08,5 Large-Cap Stocks With Growth in the Tank,https://cdn.snapi.dev/images/v1/c/a/cahs82-1.jpg,InvestorPlace,Investors looking for the safety of large-cap stocks alongside impressive growth should consider these five investments.,https://investorplace.com/2019/10/5-large-cap-stocks-with-growth-in-the-tank/,0.3818,0.8271
VRTX,2019-10-08,3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year,https://cdn.snapi.dev/images/v1/s/r/vert2.jpg,The Motley Fool,The market has yet to recognize Vertex's accelerating cash flow and growing future prospects.,https://www.fool.com/investing/2019/10/08/3-reasons-vertex-pharmaceuticals-is-poised-for-a-b.aspx,0.25,0.4404
VRTX,2019-10-02,Vertex Enters Into Collaboration With Privately-Held Ribometrix,https://cdn.snapi.dev/images/v1/m/y/biotech33.jpg,Zacks Investment Research,"Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.",https://www.zacks.com/stock/news/545835/vertex-enters-into-collaboration-with-privately-held-ribometrix,0.0,0.4404
VRTX,2019-10-02,Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock,https://cdn.snapi.dev/images/v1/v/j/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5409982fgettyimages-1140779660jpgw700opresize.jpg,The Motley Fool,"Despite working together on a major project, these two biotech stocks couldn't be more different from a growth perspective.",https://www.fool.com/investing/2019/10/02/forget-vertex-pharmaceuticals-crispr-therapeutics.aspx,0.5574,0.4336
VRTX,2019-10-01,3  Top Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/4/g/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5410062ffemale-scientist-holding-2-test-tubesjpgw700opresize.jpg,The Motley Fool,These biotech stocks are great picks -- but for very different reasons.,https://www.fool.com/investing/2019/10/01/3-top-biotech-stocks-to-buy-right-now.aspx,0.2023,0.3716
VRTX,2019-09-30,Jefferies Has 4 Red-Hot Growth Stocks to Buy With Huge Upside Potential,https://cdn.snapi.dev/images/v1/e/t/etf35-19.jpg,24/7 Wall Street,"More and more, the companies that we cover on Wall Street are starting to agree that while the future’s still reasonably bright for the U.S. economy, it may be one of stock market gains that are much lower than the norm has been over the past 10 years.",https://247wallst.com/investing/2019/09/30/jefferies-has-4-red-hot-growth-stocks-to-buy-with-huge-upside-potential/,0.5994,0.6808
VRTX,2019-09-30,"These stocks are a 'must own,' Wall Street analysts say",https://cdn.snapi.dev/images/v1/e/t/etf26.jpg,CNBC,Wall Street analysts say investors should own these stocks.,https://www.cnbc.com/2019/09/29/these-stocks-are-a-must-own-analysts-say.html,0.0,0.0
VRTX,2019-09-27,"3 Big Stock Charts for Friday: Conagra Brands, HollyFrontier and Vertex Pharmaceuticals",https://cdn.snapi.dev/images/v1/4/f/stocksup.jpg,InvestorPlace,"The stock charts of CAG, VRTX and HFC are poised to end the trading week in pivotal situations. Here's what you should know about each.",https://investorplace.com/2019/09/3-big-stock-charts-for-friday-conagra-brands-hollyfrontier-and-vertex-pharmaceuticals/,0.0,0.25
VRTX,2019-09-23,3 Top Healthcare Stocks - to Buy Right Now,https://cdn.snapi.dev/images/v1/n/f/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5401092fdoctor-holding-tablet-pc-with-images-of-dna-and-medical-stuffjpgw700opresize.jpg,The Motley Fool,Success is in these three great healthcare stocks' DNA.,https://www.fool.com/investing/2019/09/23/3-top-healthcare-stocks-to-buy-right-now.aspx,0.2023,0.8316
VRTX,2019-09-23,Better Buy:  Vertex Pharmaceuticals vs Galapagos,https://cdn.snapi.dev/images/v1/g/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5402072ffemale-scientist-holding-2-test-tubesjpgw700opresize.jpg,The Motley Fool,Which stock wins in a matchup between these two successful biotechs?,https://www.fool.com/investing/2019/09/22/better-buy-vertex-pharmaceuticals-vs-galapagos.aspx,0.4404,0.8176
VRTX,2019-09-23,2 Pharma Stocks You Should Buy Now,https://cdn.snapi.dev/images/v1/3/o/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5398792fbiotech-largejpgw700opresize.jpg,The Motley Fool,Both Vertex and Merck dominate their respective segments of the pharmaceutical market.,https://www.fool.com/investing/2019/09/21/2-pharma-stocks-you-should-buy-now.aspx,0.0,0.3182
VRTX,2019-09-20,3 Big Biotech Stocks Worth Adding to Your Portfolio Now,https://cdn.snapi.dev/images/v1/k/h/biotech35.jpg,Zacks Investment Research,We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.,https://www.zacks.com/stock/news/527589/3-big-biotech-stocks-worth-adding-to-your-portfolio-now,0.2263,0.7003
VRTX,2019-09-16,3 Top Stocks You Can Buy  and Hold for the Next Decade,https://cdn.snapi.dev/images/v1/i/x/214-5.jpg,The Motley Fool,Great business models. Great growth prospects.,https://www.fool.com/investing/2019/09/16/3-top-stocks-you-can-buy-and-hold-for-the-next-dec.aspx,0.2023,0.9186
VRTX,2019-09-13,Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland,https://cdn.snapi.dev/images/v1/g/t/biotech13.jpg,Zacks Investment Research,Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.,https://www.zacks.com/stock/news/516985/vertex-gains-reimbursement-for-orkambi-symkevi-in-scotland,0.34,0.3182
VRTX,2019-09-11,Vertex Makes Substantial Strides In Diversifying Its Pipeline,https://cdn.snapi.dev/images/v1/g/k/biotech22.jpg,Seeking Alpha,"Vertex pays $950 million in cash to acquire Semma Therapeutics, with the transaction expected to close in Q4 of 2019.",https://seekingalpha.com/article/4291067-vertex-makes-substantial-strides-diversifying-pipeline,0.2023,0.0
VRTX,2019-09-04,"Don’t Blink or You’ll Miss Vertex’s Next Move, And It’s Bound to Be a Good One",https://cdn.snapi.dev/images/v1/0/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5387292ffinancial-health-stethoscope-money-cash-hundred-bills-medical-healthcarejpgw700opresize.jpg,The Motley Fool,The pharma and biotech industries are high risk. But Vertex Pharmaceuticals is boldly soldiering on and wisely investing where it has a competitive advantage.,https://www.fool.com/investing/2019/09/04/dont-blink-or-youll-miss-vertexs-next-move-and-its.aspx,0.3182,0.7096
VRTX,2019-09-04,Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M,https://cdn.snapi.dev/images/v1/e/m/biotech13.jpg,Zacks Investment Research,Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.,https://www.zacks.com/stock/news/501399/vertex-vrtx-inks-all-cash-deal-to-acquire-semma-for-%24950m,0.0,0.0
VRTX,2019-09-04,Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff,https://cdn.snapi.dev/images/v1/k/w/biotech12.jpg,The Motley Fool,The biotech just announced a potentially game-changing acquisition.,https://www.fool.com/investing/2019/09/04/vertex-pharmaceuticals-950-million-bet-on-curing-t.aspx,0.0,0.0
VRTX,2019-09-03,Vertex Scores Key Analyst Upgrade on Top of Making an Acquisition,https://cdn.snapi.dev/images/v1/a/x/biotech2.jpg,24/7 Wall Street,"Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has seen a lot of choppy trading in 2019, rising from about $164 at the start of the year to near $195 during the first month of 2019 alone.",https://247wallst.com/healthcare-business/2019/09/03/vertex-scores-key-analyst-upgrade-on-top-of-making-an-acquisition/,0.2023,-0.25
VRTX,2019-09-03,Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M,https://cdn.snapi.dev/images/v1/h/u/diabetes-777002-1920-2.jpg,Benzinga,"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) will acquire Semma Therapeutics, a privately held biotechnology company that uses of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash.",https://www.benzinga.com/general/biotech/19/09/14365700/vertex-to-acquire-diabetes-treatment-company-semma-therapeutics-for-950m,0.0,0.0
VRTX,2019-09-02,3 Healthcare Stocks That Have a Killer Advantage,https://cdn.snapi.dev/images/v1/o/l/medical28.jpg,The Motley Fool,"These healthcare winners have such strong competitive advantages that their theme song could be MC Hammer's ""U Can't Touch This.""",https://www.fool.com/investing/2019/09/01/3-healthcare-stocks-that-have-a-killer-advantage.aspx,-0.5106,0.8625
VRTX,2019-08-28,"Three Top Biotech Stocks, to Buy Right Now",https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5378762fnew-biotechjpgw700opresize.jpg,The Motley Fool,Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.,https://www.fool.com/investing/2019/08/28/3-top-biotech-stocks-to-buy-right-now.aspx,0.2023,0.2732
VRTX,2019-08-27,"Vertex Energy, Inc: With IMO-2020 Around The Corner It's Time To Revisit This Refiner",https://cdn.snapi.dev/images/v1/p/z/biotech18.jpg,Seeking Alpha,"VTNR is well positioned to benefit from increased demand and, likely, higher prices, for IMO 2020 compliant low sulphur fuel sales beginning January 1st, 2020.",https://seekingalpha.com/article/4288170-vertex-energy-inc-imominus-2020-around-corner-time-revisit-refiner,0.2732,0.5574
VRTX,2019-08-27,"3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands",https://cdn.snapi.dev/images/v1/3/d/3d7c5b2146ac04ffd51752e17ff2a619.jpg,InvestorPlace,"The stock charts of FTI, VRTX and STZ are knocking on the doors of major moves, even if the broad market isn't.
The post 3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands appeared first on InvestorPlace.",https://investorplace.com/2019/08/3-big-stock-charts-for-tuesday-technipfmc-plc-vertex-pharmaceuticals-and-constellation-brands/,0.0,0.0
VRTX,2019-08-26,Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses,https://cdn.snapi.dev/images/v1/3/o/biotech5.jpg,24/7 Wall Street,Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.,https://247wallst.com/healthcare-business/2019/08/26/vertex-pharmaceuticals-and-other-biotech-stocks-with-recent-golden-crosses/,0.0,-0.5994
VRTX,2019-08-20,"Vertex Pharmaceuticals Inc (VRTX) EVP, Global Research and CSO David Altshuler Sold $2.3 million of Shares",https://cdn.snapi.dev/images/v1/9/m/biotech14.jpg,GuruFocus,"EVP, Global Research and CSO of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) David Altshuler (insider trades) sold 12,501 shares of VRTX on 08/19/2019 at an average price of $186.38 a share.",https://www.gurufocus.com/news/932167/vertex-pharmaceuticals-inc-vrtx-evp-global-research-and-cso-david-altshuler-sold-23-million-of-shares,0.296,0.5267
VRTX,2019-08-20,Vertex Energy's Critical Pilot Project,https://cdn.snapi.dev/images/v1/8/2/biotech8.jpg,Seeking Alpha,"After seventeen months in the works, Vertex Energy announced a partnership transaction with two phases. The transaction will both fund capital needs and help pay down long-term debt obligations.",https://seekingalpha.com/article/4286911-vertex-energys-critical-pilot-project,-0.3182,0.2263
VRTX,2019-08-20,Surging Earnings Estimates Signal Upside for Vertex (VRTX) Stock,https://cdn.snapi.dev/images/v1/r/z/biotech4.jpg,Zacks Investment Research,"Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.",https://www.zacks.com/stock/news/479497/surging-earnings-estimates-signal-upside-for-vertex-vrtx-stock,0.0,0.6808
VRTX,2019-08-12,Better Buy: Vertex Pharmaceuticals (VRTX) vs. Alexion Pharmaceuticals (ALXN),https://cdn.snapi.dev/images/v1/v/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5360042fscientists-with-dnajpgw700opresize.jpg,The Motley Fool,Two great biotechs focused on rare diseases. But one of them gets the nod as the better pick.,https://www.fool.com/investing/2019/08/11/better-buy-vertex-pharmaceuticals-vs-alexion-pharm.aspx,0.4404,0.8625
VRTX,2019-08-09,The 10 Largest-Cap Growth Stocks,https://cdn.snapi.dev/images/v1/s/m/smu5.jpg,The Motley Fool,Investors know it's not easy to find companies already worth tens of billions that can still expand their revenues rapidly. But these giants show it's not impossible.,https://www.fool.com/investing/2019/08/09/the-10-largest-cap-growth-stocks.aspx,0.3818,0.2008
VRTX,2019-08-08,Is Vertex (VRTX) a Great Growth Stock?,https://cdn.snapi.dev/images/v1/w/c/biotech7.jpg,Zacks Investment Research,"If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).",https://www.zacks.com/stock/news/461209/is-vertex-vrtx-a-great-growth-stock,0.7717,0.5994
VRTX,2019-08-07,"Vertex Energy, Inc. (VTNR) CEO Benjamin Cowart on Q2 2019 Results - Earnings Call Transcript",https://cdn.snapi.dev/images/v1/d/y/transcript22.jpg,Seeking Alpha,"Vertex Energy, Inc. (VTNR) CEO Benjamin Cowart on Q2 2019 Results - Earnings Call Transcript",https://seekingalpha.com/article/4282951-vertex-energy-inc-vtnr-ceo-benjamin-cowart-q2-2019-results-earnings-call-transcript?source=feed_sector_transcripts,0.2732,0.2732
VRTX,2019-08-06,"Vertex Pharmaceuticals Inc (VRTX) EVPChief Commercial Officer Stuart A Arbuckle Sold $657,132.",https://cdn.snapi.dev/images/v1/f/h/biotech34.jpg,GuruFocus,"EVP\Chief Commercial Officer of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stuart A Arbuckle (insider trades) sold 3,708 shares of VRTX on 08/05/2019 at an average price of $177.22 a share.",https://www.gurufocus.com/news/923237/vertex-pharmaceuticals-inc-vrtx-evpchief-commercial-officer-stuart-a-arbuckle-sold-657132-of-shares,0.0,0.5267
VRTX,2019-08-06,"Vertex Has ""Significant Financial Firepower""",https://cdn.snapi.dev/images/v1/8/g/etf29-37.jpg,The Motley Fool,A dominant cystic fibrosis franchise drives cash flow.,https://www.fool.com/investing/2019/08/06/vertex-has-significant-financial-firepower.aspx,0.2023,0.0
VRTX,2019-08-05,Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?,https://cdn.snapi.dev/images/v1/4/5/biotech5-9.jpg,The Motley Fool,Find out how concerned Vertex investors should be about a potential new cystic fibrosis treatment.,https://www.fool.com/investing/2019/08/04/what-you-need-to-know-about-the-asteroid-heading-t.aspx,0.0,0.0
VRTX,2019-08-01,"Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View",https://cdn.snapi.dev/images/v1/j/l/biotech11.jpg,Zacks Investment Research,"Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.",https://www.zacks.com/stock/news/456936/vertex-vrtx-beats-on-q2-earnings-ups-cf-product-sales-view,0.0,0.1531
VRTX,2019-07-31,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q2 2019 Results - Earnings Call Transcript,https://cdn.snapi.dev/images/v1/s/5/transcript16.jpg,Seeking Alpha,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q2 2019 Results - Earnings Call Transcript,https://seekingalpha.com/article/4279917-vertex-pharmaceuticals-incorporated-vrtx-ceo-jeff-leiden-q2-2019-results-earnings-call?source=feed_sector_transcripts,0.0,0.0
VRTX,2019-07-31,Vertex Tops Quarterly Estimates And Raises Guidance; Shares Pop,https://cdn.snapi.dev/images/v1/w/1/biotech21.jpg,Investors Business Daily,"Vertex Pharmaceuticals earnings of $1.26 per share, minus some items, on $941.3 million in sales beat Wall Street estimates Wednesday. Vertex stock jumped on raised product sales guidance.",https://www.investors.com/news/technology/vertex-earnings-vertex-stock-q2-2019/,0.6705,0.296
VRTX,2019-07-31,Is Intellia Therapeutics a Buy?,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5334052f080-birds-eye-lab-clipboardjpgw700opresize.jpg,The Motley Fool,"The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.",https://www.fool.com/investing/2019/07/31/is-intellia-therapeutics-a-buy.aspx,0.0,-0.1027
VRTX,2019-07-26,4 Biotech Stocks Sliding Lower,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5218772fbiotech3.jpg,InvestorPlace,"Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.",https://investorplace.com/2019/07/4-biotech-stocks-sliding-lower/,-0.296,0.0
VRTX,2019-07-26,Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?,https://cdn.snapi.dev/images/v1/r/s/biotech33.jpg,Zacks Investment Research,"On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.",https://www.zacks.com/stock/news/451372/vertex-vrtx-to-post-q2-earnings-whats-in-the-cards,0.0,0.0
VRTX,2019-07-25,Vertex Pharmaceuticals names Chief Medical Officer Reshma Kewalramani as new CEO,https://cdn.snapi.dev/images/v1/o/v/biotech3.jpg,Market Watch,"Vertex Pharmaceuticals Inc. VRTX, -1.08% said Thursday that it was promoting Chief Medical Officer Reshma Kewalramani to the posts of president and chief executive officer.",https://www.marketwatch.com/story/vertex-pharmaceuticals-names-chief-medical-officer-reshma-kewalramani-as-new-ceo-2019-07-25,0.0,0.3612
VRTX,2019-07-23,Is Vertex Pharmaceuticals a Buy?,https://cdn.snapi.dev/images/v1/p/h/ver.jpg,The Motley Fool,This company is making drug development look much easier than it really is.,https://www.fool.com/investing/2019/07/23/is-vertex-pharmaceuticals-a-buy.aspx,0.0,0.4215
VRTX,2019-07-15,3 Top Biotech Stocks to Buy for the 2nd Half of 2019,https://cdn.snapi.dev/images/v1/h/g/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5310742fscientist-holding-a-test-tubejpgw700opresize.jpg,The Motley Fool,Great growth prospects and relatively modest risk levels make these biotech stocks really attractive.,https://www.fool.com/investing/2019/07/14/3-top-biotech-stocks-to-buy-for-the-2nd-half-of-20.aspx?source=iedfolrf0000001,0.2023,0.8748
VRTX,2019-07-12,"3 Big Stock Charts for Friday: HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals",https://cdn.snapi.dev/images/v1/h/r/ees23.jpg,InvestorPlace,"The stock charts of HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals are poised to end the trading week in a pivotal situation.",https://investorplace.com/2019/07/3-big-stock-charts-for-friday-hollyfrontier-activision-blizzard-and-vertex-pharmaceuticals/,0.0,0.25
VRTX,2019-07-10,Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019,https://cdn.snapi.dev/images/v1/c/b/cbm-2.jpg,Investors Business Daily,"Biotech companies exploded with ""megadeals"" in the first half of 2019 as pharmaceutical companies Bristol-Myers Squibb and AbbVie announced acquisitions worth a combined $137 billion.
The post Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019 appeared first on Investor's Business Daily.",https://www.investors.com/news/technology/biotech-companies-megadeals-political-pressure-china-trends-2019/,0.0,0.2263
VRTX,2019-07-03,Why These 4 Biotech Leaders Could Rebound On Strong Earnings,https://cdn.snapi.dev/images/v1/2/9/290-9.jpg,Investors Business Daily,"Large biotech companies Gilead Sciences and Vertex Pharmaceuticals are poised to beat Wall Street's second-quarter revenue expectations, according to investment bank RBC Capital Markets.",https://www.investors.com/news/technology/biotech-companies-stocks-poised-to-beat-second-quarter-earnings-estimates/,0.5106,0.25
VRTX,2019-07-01,How to Invest in Biotech Stocks,https://cdn.snapi.dev/images/v1/l/c/biotech40.jpg,The Motley Fool,Seven simple steps to improving your chances of success in this part of the market.,https://www.fool.com/investing/2019/07/01/how-to-invest-in-biotech-stocks.aspx?source=iedfolrf0000001,0.0,0.8074
VRTX,2019-07-01,Vertex Pharmaceuticals: A Stock That Continues To Impress In 2019,https://cdn.snapi.dev/images/v1/3/s/biotech21.jpg,Seeking Alpha,"Kalydeco, Orkambi, and Symdeko continue to report robust demand trends in CF population.",https://seekingalpha.com/article/4273008-vertex-pharmaceuticals-stock-continues-impress-2019?source=feed_tag_long_ideas,0.4404,0.2263
VRTX,2019-07-01,Three Growth Stocks to Buy and Hold for the Next 50 Years,https://cdn.snapi.dev/images/v1/2/v/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5298912fa-hand-placing-a-coin-on-a-stack-of-coinsjpgw700opresize.jpg,The Motley Fool,"This alcohol maker, drug company, and utility should generate steady growth for their investors in the decades ahead.",https://www.fool.com/investing/2019/06/29/3-growth-stocks-to-buy-and-hold-for-the-next-50-ye.aspx?source=iedfolrf0000001,0.3818,0.3818
VRTX,2019-06-27,10 Names That Are Screaming Stocks to Buy,https://cdn.snapi.dev/images/v1/e/s/esy27-2.jpg,InvestorPlace,"Even in these unstable times, there are still gems to be found. These 10 stocks share a ""strong buy"" analyst consensus rating from the Street and compelling growth drivers.",https://investorplace.com/2019/06/10-stocks-that-are-screaming-buys-right-now/,-0.3818,0.7579
VRTX,2019-06-26,Vertex Pharmaceuticals Is A Good Long-Term Investment,https://cdn.snapi.dev/images/v1/s/t/biotech37.jpg,Seeking Alpha,Vertex has a high P/E compared to other large-cap biotechs.,https://seekingalpha.com/article/4272240-vertex-pharmaceuticals-good-long-term-investment?source=feed_tag_long_ideas,0.4404,0.0
VRTX,2019-06-25,The 10 Biggest Biotech Stocks,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5295332fbiotech-conceptjpgw700opresize.jpg,The Motley Fool,Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.,https://www.fool.com/investing/2019/06/25/the-10-biggest-biotech-stocks.aspx?source=iedfolrf0000001,0.0,0.296
VRTX,2019-06-24,Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children,https://cdn.snapi.dev/images/v1/t/o/biotech4.jpg,Zacks Investment Research,Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.,https://www.zacks.com/stock/news/433546/vertexs-vrtx-symdeko-gets-fda-nod-for-use-in-children,0.0,0.7845
VRTX,2019-06-24,"3 Stocks That Could Double Your Money: GH, TTD & VRTX",https://cdn.snapi.dev/images/v1/p/9/sto2934.jpg,The Motley Fool,Great businesses plus great growth opportunities could add up to 100% or more returns for these stocks.,https://www.fool.com/investing/2019/06/22/3-stocks-that-could-double-your-money.aspx?source=iedfolrf0000001,0.0,0.9246
VRTX,2019-06-20,Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $9.8 million of Shares,https://cdn.snapi.dev/images/v1/r/q/biotech22.jpg,GuruFocus,"CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 56,030 shares of VRTX on 06/18/2019 at an average price of $175.39 a share.",https://www.gurufocus.com/news/897700/vertex-pharmaceuticals-inc-vrtx-ceo--president-jeffrey-m-leiden-sold-98-million-of-shares,0.296,0.5267
VRTX,2019-06-20,Check Out These 5 Fast-Growing Stocks to Buy Today,https://cdn.snapi.dev/images/v1/e/t/etf23-34.jpg,InvestorPlace,"Growth is on a different track now, and here are some great ideas for stocks to buy to ride the momentum.",https://investorplace.com/2019/06/7-fast-growing-stocks-to-buy-today/,0.0,0.7717
VRTX,2019-06-17,Vertex Makes Strong Push Into Crispr Tech With 2 Deals At Once,https://cdn.snapi.dev/images/v1/a/z/biotech13.jpg,Seeking Alpha,"Vertex is really committed into advancing CRISPR technology to develop treatments for DMD and other neurological disorders, proven by the expanded agreement with CRISPR Therapeutics and acquisition of Exonics.",https://seekingalpha.com/article/4270691-vertex-makes-strong-push-crispr-tech-2-deals?source=feed_tag_long_ideas,0.5106,0.6801
VRTX,2019-06-17,3 Cheap Drug Stocks You Can Buy Right Now,https://cdn.snapi.dev/images/v1/l/h/jnj-2.jpg,The Motley Fool,Not all stocks are expensive. These drug stocks look like bargains.,https://www.fool.com/investing/2019/06/16/3-cheap-drug-stocks-you-can-buy-right-now.aspx?source=iedfolrf0000001,0.0,0.3612
VRTX,2019-06-14,7 Top-Rated Biotech Stocks to Invest In Today,https://cdn.snapi.dev/images/v1/b/i/biotechmsn.jpg,InvestorPlace,"Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.",https://investorplace.com/2019/06/7-healthy-biotech-stocks-to-invest-in/,0.0,0.4692
VRTX,2019-06-14,"3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics",https://cdn.snapi.dev/images/v1/e/t/etf29-37.jpg,InvestorPlace,"Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.",https://investorplace.com/2019/06/3-big-stock-charts-for-friday-symantec-vertex-pharmaceuticals-and-nektar-therapeutics/,0.0,0.0
VRTX,2019-06-12,5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5284572ffemale-scientist-with-pipette-in-labjpgw700opresize.jpg,The Motley Fool,New blockbusters could be on the way for five drugmakers.,https://www.fool.com/investing/2019/06/12/5-most-valuable-pipeline-drugs-in-development-and.aspx?source=iedfolrf0000001,0.807,0.0
VRTX,2019-06-11,Crispr: Vertex Doubled Down On The Reigning Champion CRISPR/Cas9,https://cdn.snapi.dev/images/v1/k/u/biotech19.jpg,Seeking Alpha,"Due to its stellar CRISPR/Cas9 platform, CRISPR Therapeutics is able to expand its collaborative relationship with the pharmaceutical elite, Vertex.",https://seekingalpha.com/article/4269689-crispr-vertex-doubled-reigning-champion-crispr-cas9?source=feed_tag_long_ideas,0.5994,0.3182
VRTX,2019-06-11,CELG or VRTX: Which Is the Better Value Stock Right Now?,https://cdn.snapi.dev/images/v1/n/u/biotech12.jpg,Zacks Investment Research,CELG vs. VRTX: Which Stock Is the Better Value Option?,https://www.zacks.com/stock/news/427825/celg-or-vrtx-which-is-the-better-value-stock-right-now,0.6486,0.6486
VRTX,2019-06-10,3 Healthcare Stocks I'd Buy Right Now,https://cdn.snapi.dev/images/v1/s/e/se23-6.jpg,The Motley Fool,"Illumina, Teladoc Health, and Vertex Pharmaceuticals enjoy strong competitive advantages and great growth opportunities.",https://www.fool.com/investing/2019/06/09/3-healthcare-stocks-id-buy-right-now.aspx?source=iedfolrf0000001,0.0,0.9584
VRTX,2019-06-10,Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?,https://cdn.snapi.dev/images/v1/b/i/biotech38-8.jpg,The Motley Fool,"Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.",https://www.fool.com/investing/2019/06/09/gene-therapy-vs-gene-editing-which-is-better-for-t.aspx?source=iedfolrf0000001,0.4404,0.1154
VRTX,2019-06-07,Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing,https://cdn.snapi.dev/images/v1/s/l/biotech9.jpg,Investors Business Daily,"Vertex Pharmaceuticals is betting on gene-editing treatments with the acquisition of private biotech company Exonics Therapeutics and a deeper collaboration with Crispr Therapeutics.
The post Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing appeared first on Investor's Business Daily.",https://www.investors.com/news/technology/biotech-companies-buying-spree-gene-editing-treatments/,0.0,0.0
VRTX,2019-06-07,"Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion",https://cdn.snapi.dev/images/v1/d/n/dna-3656587-1920-0.jpg,Benzinga,"Gene editing is an emerging field, and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)  is plunging headlong into it with two deals announced Thursday after the market close.",https://www.benzinga.com/general/biotech/19/06/13881293/vertex-signs-gene-editing-deals-with-crispr-exonics-worth-up-to-2-billion,0.2263,0.0
VRTX,2019-06-07,"Vertex Expands Collaboration With CRISPR, Acquires Exonics",https://cdn.snapi.dev/images/v1/b/9/biotech8.jpg,Zacks Investment Research,Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.,https://www.zacks.com/stock/news/426146/vertex-expands-collaboration-with-crispr-acquires-exonics,0.1027,0.0
VRTX,2019-06-05,Vertex's Latest Data May Lead To Expanded Cystic Fibrosis Market,https://cdn.snapi.dev/images/v1/h/w/biotech2.jpg,Seeking Alpha,Vertex picks VX-445 as triplet therapy to move on with for regulatory approval in the U.S. and European Union to treat patients with cystic fibrosis.,https://seekingalpha.com/article/4268568-vertexs-latest-data-may-lead-expanded-cystic-fibrosis-market?source=feed_tag_long_ideas,0.0,0.7003
VRTX,2019-06-04,5 Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/o/u/biotech13.jpg,Zacks Investment Research,here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.,https://www.zacks.com/stock/news/424754/5-biotech-stocks-to-buy-right-now,0.0,0.6705
VRTX,2019-05-31,Vertex Selects Triple Combo Regimen for Regulatory Submission,https://cdn.snapi.dev/images/v1/w/8/vertex-2.jpg,Zacks Investment Research,Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.,https://www.zacks.com/stock/news/422781/vertex-selects-triple-combo-regimen-for-regulatory-submission,0.0,0.4767
VRTX,2019-05-30,This Biotech Just Inched Closer To Treating 90% Of Cystic Fibrosis Patients,https://cdn.snapi.dev/images/v1/v/e/ver-2.jpg,Investors Business Daily,Vertex Pharmaceuticals said Thursday it selected the three-drug cystic fibrosis treatment it plans to submit to regulators in the U.S. and Europe.,https://feedproxy.google.com/~r/InternetTechnologyRss/~3/0iVR6n3mmkY/,0.0,0.0
VRTX,2019-05-30,Why Is Vertex (VRTX) Down 3.5% Since Last Earnings Report?,https://cdn.snapi.dev/images/v1/p/2/biotech34.jpg,Zacks Investment Research,Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?,https://www.zacks.com/stock/news/422166/why-is-vertex-vrtx-down-35-since-last-earnings-report,0.0,0.0
VRTX,2019-05-29,3 Large-Cap Stocks With Superior Performances,https://cdn.snapi.dev/images/v1/e/t/etf26-22.jpg,GuruFocus,"Several large-cap stocks have had positive performances over the past month, year to date, the last 12 months and past three years.",https://www.gurufocus.com/news/886199/3-largecap-stocks-with-superior-performances-,0.5423,0.5574
VRTX,2019-05-28,Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $19.9 million of Shares,https://cdn.snapi.dev/images/v1/j/1/biotech7.jpg,GuruFocus,"CEO & President of Vertex Pharmaceuticals Inc. Jeffrey M Leiden sold 113,432 shares of VRTX on 05/24/2019 at an average price of $175.1 a share.",https://www.gurufocus.com/news/885963/vertex-pharmaceuticals-inc-vrtx-ceo--president-jeffrey-m-leiden-sold-199-million-of-shares,0.296,0.5267
VRTX,2019-05-27,3 Big Biotech Stocks That Warren Buffett Might Like,https://cdn.snapi.dev/images/v1/b/u/bu8s3.jpg,The Motley Fool,There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.,https://www.fool.com/investing/2019/05/26/3-big-biotech-stocks-warren-buffett-might-like.aspx?source=iedfolrf0000001,0.3612,0.0
VRTX,2019-05-13,5 Growthy Biotech Stocks to Buy Despite the Scrutiny,https://cdn.snapi.dev/images/v1/0/9/092314-0028-nvsholdwith1.jpg,InvestorPlace,Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?,https://feedproxy.google.com/~r/InvestorPlace/~3/yuNrJUL6pnI/,0.0,0.4404
VRTX,2019-05-13,My Top Stock to Buy in May,https://cdn.snapi.dev/images/v1/x/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5245142fscientist-holding-a-test-tubejpgw700opresize.jpg,The Motley Fool,This biotech checks off the two most important criteria that the greatest stocks have.,https://www.fool.com/investing/2019/05/12/heres-my-top-stock-to-buy-in-may.aspx?source=iedfolrf0000001,0.2023,0.7425
VRTX,2019-05-08,CELG vs. VRTX: Which Stock Should Value Investors Buy Now?,https://cdn.snapi.dev/images/v1/h/b/biotech13.jpg,Zacks Investment Research,CELG vs. VRTX: Which Stock Is the Better Value Option?,https://www.zacks.com/stock/news/410995/celg-vs-vrtx-which-stock-should-value-investors-buy-now,0.34,0.6486
VRTX,2019-05-02,"Vertex Pharmaceuticals Looks to Jump From 18,000 Patients to 68,000",https://cdn.snapi.dev/images/v1/t/f/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5230852fcystic-fibrosis.jpg,The Motley Fool,The biotech's cystic fibrosis treatment potential is far from over.,https://www.fool.com/investing/2019/05/02/vertex-pharmaceuticals-looks-to-jump-from-18000-pa.aspx?source=iedfolrf0000001,0.0,0.0
VRTX,2019-05-02,5 Things You Need to Know From Vertex Pharmaceuticals' Q1 Earnings Update,https://cdn.snapi.dev/images/v1/p/i/vert2.jpg,The Motley Fool,Vertex started off 2019 on a positive note. But even better days are almost certainly on the way.,https://www.fool.com/investing/2019/05/02/5-things-you-need-to-know-from-vertex-pharmaceutic.aspx?source=iedfolrf0000001,0.0,0.8228
VRTX,2019-05-01,Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates,https://cdn.snapi.dev/images/v1/t/a/biotech28.jpg,Zacks Investment Research,"Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.",https://www.zacks.com/stock/news/406789/vertex-vrtx-q1-earnings-and-revenues-surpass-estimates,0.0,-0.128
VRTX,2019-04-30,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q1 2019 Results - Earnings Call Transcript,https://cdn.snapi.dev/images/v1/f/b/transcript41.jpg,Seeking Alpha,Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q1 2019 Results - Earnings Call Transcript,https://seekingalpha.com/article/4258360-vertex-pharmaceuticals-incorporated-vrtx-ceo-jeff-leiden-q1-2019-results-earnings-call?source=feed_sector_transcripts,0.0,0.0
VRTX,2019-04-30,Cystic Fibrosis-Focused Biotech Easily Tops First-Quarter Estimates,https://cdn.snapi.dev/images/v1/v/e/vertex-3.jpg,Investors Business Daily,Vertex earnings of $1.14 a share on $857 million in sales beat the forecasts of Wall Street analysts when it reported late Tuesday. But Vertex stock remained flat in after-hours action.,https://feedproxy.google.com/~r/InternetTechnologyRss/~3/gMUd3ZPHvus/,0.6908,0.296
VRTX,2019-04-29,Top Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5213462fscientists-working-in-lab.jpg,The Motley Fool,The future looks incredibly bright for these three businesses.,https://www.fool.com/investing/2019/04/28/3-top-biotech-stocks-to-buy-right-now.aspx?source=iedfolrf0000001,0.2023,0.4927
VRTX,2019-04-24,What's in Store for Vertex (VRTX) This Earnings Season?,https://cdn.snapi.dev/images/v1/7/0/biotech22.jpg,Zacks Investment Research,"On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.",https://www.zacks.com/stock/news/398972/whats-in-store-for-vertex-vrtx-this-earnings-season,0.0,0.2732
VRTX,2019-04-24,Everything You Need to Know About Investing in Healthcare,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5199432fhealthcare-icons-on-wood-blocks.jpg,The Motley Fool,The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.,https://www.fool.com/investing/2019/04/24/everything-you-need-to-know-about-investing-in.aspx?source=iedfolrf0000001,0.0,0.6597
VRTX,2019-04-22,Two investors make the case for why now is the time to invest in health care stocks,https://cdn.snapi.dev/images/v1/m/q-3/two-investors-make-the-case-for-why-now-is-the-time-to-invest-in-health-care-stocks.jpg,CNBC Television,"Michael Yee, Jefferies Biotech analyst, and Les Funtleyder, E-Squared Capital Management, join 'The Exchange' to discuss the health care sector and why investors are taking their bets off the stocks.",https://www.youtube.com/watch?v=C95nFfG5VRA,0.4939,0.6597
VRTX,2019-04-19,5 Top Pharmaceutical Stocks to Buy in 2019,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5178452fscientist-holding-a-test-tube.jpg,The Motley Fool,"Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.",https://www.fool.com/investing/2019/04/19/5-top-pharmaceutical-stocks-to-buy-in-2019.aspx?source=iedfolrf0000001,0.2023,0.6369
VRTX,2019-04-19,5 Top Biotech Stocks to Buy in 2019,https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5122902ftest-tubes-with-arrow.jpg,The Motley Fool,Looking for potential winning biotech stocks? These five check off all the boxes for investors.,https://www.fool.com/investing/2019/04/19/5-top-biotech-stocks-to-buy-in-2019.aspx?source=iedfolrf0000001,0.2023,0.5267
VRTX,2019-04-19,5 Top Healthcare Stocks to Buy in 2019,https://cdn.snapi.dev/images/v1/h/c/hc6-2.jpg,The Motley Fool,"Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.",https://www.fool.com/investing/2019/04/19/5-top-healthcare-stocks-to-buy-in-2019.aspx?source=iedfolrf0000001,0.2023,0.2023
VRTX,2019-04-17,Pharmas That Own Their Markets,https://cdn.snapi.dev/images/v1/v/e/vert2-2.jpg,Forbes,"To take some of the complexity of investing in pharma stocks, look at the companies that dominate their markets.",https://www.forbes.com/sites/kenberman/2019/04/17/pharmas-that-own-their-markets/,0.0,-0.128
VRTX,2019-04-17,"Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag",https://cdn.snapi.dev/images/v1/b/i/biotech5-9.jpg,Zacks Investment Research,"FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.",https://www.zacks.com/stock/news/382503/vertex-crisprs-gene-editing-drug-gets-fdas-fast-track-tag,0.0,0.2263
VRTX,2019-04-09,Why Vertex Pharmaceuticals Could Conceivably Succeed Too Well,https://cdn.snapi.dev/images/v1/v/e/ver.jpg,The Motley Fool,The sky is the limit for this biotech leader.,https://www.fool.com/investing/2019/04/09/why-vertex-pharmaceuticals.aspx?source=iedfolrf0000001,0.6486,0.0
VRTX,2019-04-01,Biotech Stocks to Buy Right Now,https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5176442fscientist-holding-a-test-tube.jpg,The Motley Fool,These biotech stocks could have a lot of room to run.,https://www.fool.com/investing/2019/03/31/3-top-biotech-stocks-to-buy-right-now.aspx?source=iedfolrf0000001,0.0,0.0
VRTX,2019-03-29,Celgene and Vertex Pharmaceuticals ?,https://cdn.snapi.dev/images/v1/b/i/biotech26.jpg,Zacks Investment Research,Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Celgene and Vertex Pharmaceuticals. But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.,https://www.zacks.com/stock/news/366969/celg-or-vrtx-which-is-the-better-value-stock-right-now,0.0,0.7845
VRTX,2019-03-25,Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable,https://cdn.snapi.dev/images/v1/v/e/vert2.jpg,Investors Business Daily,"A tiny biotech called Proteostasis won't be able to rival Vertex in cystic fibrosis treatment, analysts said Monday. Proteostasis' triple-medicine missed the bar set by Vertex's.",https://feedproxy.google.com/~r/InternetTechnologyRss/~3/ve8cj1MX_Sc/,0.6249,-0.296
VRTX,2019-03-25,Better Buy:  Vertex Pharmaceuticals vs.  Regeneron Pharmaceuticals,https://cdn.snapi.dev/images/v1/p/h/pharma12.jpg,The Motley Fool,Which stock wins in a battle between these two successful biotechs?,https://www.fool.com/investing/2019/03/24/better-buy-vertex-pharmaceuticals-vs-regeneron-pha.aspx?source=iedfolrf0000001,0.4404,0.7096
VRTX,2019-03-19,Biotech Giant Tumbles On Downgrade Amid Payer Pushback In Europe,https://cdn.snapi.dev/images/v1/v/e/vertex-2.jpg,Investors Business Daily,Vertex Pharmaceuticals stock slipped below its 50-day moving average Tuesday after sustaining a downgrade and price target cut on European opposition to its cystic fibrosis treatments.,https://feedproxy.google.com/~r/BusinessRss/~3/OEouwjf0CbI/,0.0,-0.2732
VRTX,2019-03-11,Why Vertex's Dilemma Makes It the Best Biotech Stock to Buy Now,https://cdn.snapi.dev/images/v1/v/e/vertex-1.jpg,The Motley Fool,Excellent clinical trial results are giving Vertex a problem most biotechs wish they had.,https://www.fool.com/investing/2019/03/10/does-vertexs-dilemma-make-it-the-best-biotech-stoc.aspx?source=iedfolrf0000001,0.5423,0.749
VRTX,2019-03-11,Stocks This Week: Short Vertex Pharmaceuticals,https://cdn.snapi.dev/images/v1/v/e/vertex.jpg,Forbes,Vertex Pharmaceuticals is picked up by the cycle scan. The weekly price cycle gives a sell signal on March 13th.,https://www.forbes.com/sites/greatspeculations/2019/03/10/stocks-this-week-buy-micron-and-short-vertex-pharmaceuticals/#2215d11437d4,0.0,0.0
VRTX,2019-02-05,MARKET UPDATE: Vertex Pharmaceuticals Incorporated,https://cdn.snapi.dev/images/v1/p/l/plw-cuhdlfwv-3.jpg,Investors Business Daily,Investor's Business Daily's MARKET UPDATE with Alissa Coram and Ken Shreve.,https://www.youtube.com/watch?v=PLW-cUHDLfw&t=291s,0.0,0.0
VRTX,2019-01-09,Indexes Open Lower; Retailers Slump On Holiday Sales,https://cdn.snapi.dev/images/v1/s/-/s-dycwio8y4.jpg,Investors Business Daily,Alissa Coram & Ken Shreve´s market update,https://www.youtube.com/watch?v=s-DycwiO8Y4,0.128,0.0
VRTX,2018-10-23,"Dow fades early gain; Boeing rises, Texas Instruments slumps.",https://cdn.snapi.dev/images/v1/f/o/fod4hnm01jm.jpg,Investors Business Daily,Ken Shreve & Alissa Coram´s analyses stock´s behavior..,https://www.youtube.com/watch?v=fOd4HNM01JM,0.5267,0.0
